Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

17
results for

"Young Lee"

Article category

Keywords

Publication year

"Young Lee"

Original Articles

GAFAD: An LC-MS/MS–Based Model for Early Hepatocellular Carcinoma Detection Beyond GALAD’s Limitation
Hyojin Kim, Wonseok Oh, Juri Park, Saeyoung Lee, Won Suk Yang, Soon Sun Kim, Jae Youn Cheong, Je-Hyun Baek
Received October 31, 2025  Accepted February 23, 2026  Published online February 25, 2026  
DOI: https://doi.org/10.3350/cmh.2025.1244    [Accepted]
Background/Aims
The GALAD (Gender, Age, Lens culinaris agglutinin-reactive alpha-fetoprotein [AFP-L3], alpha-fetoprotein [AFP], and des-γ-carboxy prothrombin [DCP]) score, widely used for hepatocellular carcinoma (HCC) detection, was primarily derived from cohorts with advanced-stage tumors and elevated biomarker levels, potentially overestimating accuracy in early-stage disease. Furthemore, the lectin-based AFP-L3 assay has poor sensitivity at low AFP concentrations, limiting detection of small or AFP-negative tumors.
Methods
We developed GAFAD, a multivariable model replacing AFP-L3 with fucosylated AFP percentage (AFP-Fuc%), quantified by a validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay. The model was trained and tested using a hepatitis B virus (HBV)-related cohort (HCC n=235; non-HCC n=290), a diagnostically challenging set with substantial overlap in biomarker levels between HCC and non-HCC. Moreover, a final model (GAFAD) was validated in two independent cohorts (HCC n=210, non-HCC n=245), comprising HBV-, HCV-related and non-viral etiologies.
Results
In the development cohort, GAFAD showed superior diagnostic performance to GALAD for distinguishing HCC from non-HCC, with a higher area under the receiver operating characteristic curve (AUC, 0.938 vs. 0.887; p<0.0001) and greater sensitivity (82% vs. 66%) and accuracy (86% vs. 79%) at 90% specificity. In the external validation cohort, GAFAD similarly outperformed GALAD, achieving a higher AUC (0.874 vs. 0.841, p<0.05), greater sensitivity (72% vs. 57%), and improved accuracy (82% vs. 75%) at 90% specificity. This superiority extended to early-stage, very-early-stage, and AFP-negative HCC.
Conclusions
GAFAD provides a reliable and generalizable tool for early HCC detection across diverse etiologies, supporting its clinical applicability in surveillance and diagnosis.
  • 1,113 View
  • 105 Download
Novel near-infrared probe for monitoring lipid peroxidation-mediated viscosity change in ferroptotic hepatocytes video
Le Bich Hang Pham, Taeeung Kim, Seoyoung Kim, Yun Seok Kim, Jiyeon Kim, Kyeongseon Kim, Hyeonwoo Lim, Wan Seob Shim, Byoungmo Kim, So-Yeol Yoo, Jae-Young Lee, Murim Choi, Won Kim, Keon Wook Kang, Jeeyeon Lee
Clin Mol Hepatol 2026;32(1):318-338.
Published online November 17, 2025
DOI: https://doi.org/10.3350/cmh.2025.0779
Background/Aims
Ferroptosis, recently emerged as a new cell death modality characterized by iron-dependent peroxidation of lipids, has been explored in various diseases. However, detection of ferroptosis, particularly in chronic liver disease models, is hampered by the lack of universal ferroptosis markers and limited number of fluorescence sensors for in vivo ferroptosis.
Methods
In this study, we developed TTM-4 as a highly sensitive near-infrared (NIR) fluorescent probe to detect ferroptosis.
Results
TTM-4 exhibited turn-on fluorescence upon viscosity change, enabling visualization of lipid peroxidation (LPO) in ferroptotic hepatocytes and liver tissue samples with greater sensitivity than BODIPY 581/591 C11. Timelapse live-cell imaging of erastin-treated cells revealed real-time LPO dynamics involving cytosolic lipid droplets (cLDs), endoplasmic reticulum, and nuclear LDs in a chronological order. Further gene expression analysis of 216 liver tissue samples from the NCBI GEO database showed a significant increase in CIDEC concurrent with TTM-4 fluorescence during progression to metabolic dysfunction-associated steatotic hepatitis (MASH). TTM-4, with its low toxicity and turn-on NIR emission during ferroptosis, also enabled in vivo visualization of ferroptosis in liver injury and metabolic dysfunction-associated steatotic liver disease (MASLD) models.
Conclusions
Our findings suggest that TTM-4 enables monitoring of ferroptosis in MASLD and would aid in early MASH diagnosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Targeting ferroptosis to halt MASLD and MASH
    Fudi Wang
    Trends in Endocrinology & Metabolism.2026;[Epub]     CrossRef
  • 3,288 View
  • 259 Download
  • Crossref

Hepatic neoplasm

Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma
Da-Won Kim, Jin Hyun Park, Suk Kyun Hong, Min-Hyeok Jung, Ji-One Pyeon, Jin-Young Lee, Kyung-Suk Suh, Nam-Joon Yi, YoungRok Choi, Kwang-Woong Lee, Young-Joon Kim
Clin Mol Hepatol 2025;31(2):563-576.
Published online January 13, 2025
DOI: https://doi.org/10.3350/cmh.2024.0899
Background/Aims
Hepatocellular carcinoma (HCC) exhibits high de novo recurrence rates post-resection. Current post-surgery recurrence prediction methods are limited, emphasizing the need for reliable biomarkers to assess recurrence risk. We aimed to develop methylation-based markers for classifying HCC patients and predicting their risk of de novo recurrence post-surgery.
Methods
In this retrospective cohort study, we analyzed data from HCC patients who underwent surgical resection in Korea, excluding those with recurrence within one year post-surgery. Using the Infinium Methylation EPIC array on 140 samples in the discovery cohort, we classified patients into low- and high-risk groups based on methylation profiles. Distinctive markers were identified through random forest analysis. These markers were validated in the cancer genome atlas (n=217), Validation cohort 1 (n=63) and experimental Validation using a methylation-sensitive high-resolution melting (MS-HRM) assay in Validation cohort 1 and Validation cohort 2 (n=63).
Results
The low-risk recurrence group (methylation group 1; MG1) showed a methylation average of 0.73 (95% confidence interval [CI] 0.69–0.77) with a 23.5% recurrence rate, while the high-risk group (MG2) had an average of 0.17 (95% CI 0.14–0.20) with a 44.1% recurrence rate (P<0.03). Validation confirmed the applicability of methylation markers across diverse populations, showing high accuracy in predicting the probability of HCC recurrence risk (area under the curve 96.8%). The MS-HRM assay confirmed its effectiveness in predicting de novo recurrence with 95.5% sensitivity, 89.7% specificity, and 92.2% accuracy.
Conclusions
Methylation markers effectively classified HCC patients by de novo recurrence risk, enhancing prediction accuracy and potentially offering personalized management strategies.

Citations

Citations to this article as recorded by  Crossref logo
  • Methylation of zinc-finger protein ZNF471 regulates MIS18A expression and inhibits proliferation and metastasis of hepatocellular carcinoma via negative regulation of the Wnt/β-catenin pathway, as well as enhances sensitivity to apatinib and donafenib
    Xiaofei Wang, Luyao Jia, Chao Zhang, Chunjing Bian, Chenchen Huang, Kejing Ma, Tao Luo
    Cellular Signalling.2026; 145: 112608.     CrossRef
  • 9,359 View
  • 153 Download
  • 4 Web of Science
  • Crossref

Editorial

Steatotic liver disease

Citations

Citations to this article as recorded by  Crossref logo
  • Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
    Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon
    International Journal of Molecular Sciences.2025; 26(19): 9715.     CrossRef
  • JAB1/CRL4B complex represses PPARG/ACSL5 expression to promote breast tumorigenesis
    Ting Hu, Tianyu Ma, Miaomiao Huo, Jiaxiang Liu, Die Zhang, Yu Li, Jinyuan Chang, Min Zhang, Yinuo Wang, Tianyang Gao, Baowen Yuan, Siqi Wang, Qing Li, Xiaoqi Ma, Jingyao Zhang, Wei Huang, Yan Wang
    Cell Death & Differentiation.2025;[Epub]     CrossRef
  • 8,365 View
  • 134 Download
  • 3 Web of Science
  • Crossref

Letter to the Editor

Steatotic liver disease

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
Clin Mol Hepatol 2023;29(3):810-811.
Published online May 8, 2023
DOI: https://doi.org/10.3350/cmh.2023.0129

Citations

Citations to this article as recorded by  Crossref logo
  • Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study
    Woo-Young Shin, Eun Seok Kang, Yun Hwan Oh, Meng Sha, Qiang Xia, Seogsong Jeong, Yoosun Cho
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study
    Chae Won Lee, Eun Seok Kang, Seogsong Jeong, Hyun Wook Han, Samuel O. Antwi
    PLOS One.2025; 20(6): e0323880.     CrossRef
  • 7,647 View
  • 80 Download
  • 3 Web of Science
  • Crossref

Original Articles

Steatotic liver disease

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Na Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Suk
Clin Mol Hepatol 2021;27(1):110-124.
Published online December 3, 2020
DOI: https://doi.org/10.3350/cmh.2020.0125
Background/Aims
Nonalcoholic fatty liver disease (NAFLD) is closely related to gut-microbiome. There is a paucity of research on which strains of gut microbiota affect the progression of NAFLD. This study explored the NAFLD-associated microbiome in humans and the role of Lactobacillus in the progression of NAFLD in mice.
Methods
The gut microbiome was analyzed via next-generation sequencing in healthy people (n=37) and NAFLD patients with elevated liver enzymes (n=57). Six-week-old male C57BL/6J mice were separated into six groups (n=10 per group; normal, Western, and four Western diet + strains [109 colony-forming units/g for 8 weeks; L. acidophilus, L. fermentum, L. paracasei, and L. plantarum]). Liver/body weight ratio, liver pathology, serum analysis, and metagenomics in the mice were examined.
Results
Compared to healthy subjects (1.6±4.3), NAFLD patients showed an elevated Firmicutes/Bacteroidetes ratio (25.0±29.0) and a reduced composition of Akkermansia and L. murinus (P<0.05). In the animal experiment, L. acidophilus group was associated with a significant reduction in liver/body weight ratio (5.5±0.4) compared to the Western group (6.2±0.6) (P<0.05). L. acidophilus (41.0±8.6), L. fermentum (44.3±12.6), and L. plantarum (39.0±7.6) groups showed decreased cholesterol levels compared to the Western group (85.7±8.6) (P<0.05). In comparison of steatosis, L. acidophilus (1.9±0.6), L. plantarum (2.4±0.7), and L. paracasei (2.0±0.9) groups showed significant improvement of steatosis compared to the Western group (2.6±0.5) (P<0.05).
Conclusions
Ingestion of Lactobacillus, such as L. acidophilus, L. fermentum, and L. plantarum, ameliorates the progression of nonalcoholic steatosis by lowering cholesterol. The use of Lactobacillus can be considered as a useful strategy for the treatment of NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Black Sesame Pigment Ameliorates Non-Alcoholic Fatty Liver Disease via Modulation of the Gut–Liver Axis and HIF-1 Signaling Pathway
    Qian Huang, Zhuowen Liang, Qingpeng Li, Ke Wang, Shuang Zhu, Wei Xiao, Lin Zhou
    Antioxidants.2026; 15(2): 177.     CrossRef
  • Alteration in tongue coating microbiota across different stages of hepatitis B virus-related chronic liver disease
    Umar Pervaiz, Fuxia Wu, Pervaiz Nabeel, Rui Zhao, Zhengbin Zhao, Yibao Zhang, Peng Xia, Pengfei Ji, Xinyi Yuan, Xiaohui Hu, Zhao Guo, Kun Xie, Fang Wang, Degui Wang
    Journal of Oral Microbiology.2026;[Epub]     CrossRef
  • Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights
    Supriyo Ghosh, Amlan Jyoti Ghosh, Manab Deb Adhikari, Bipransh Kumar Tiwary, Tilak Saha
    Journal of Diabetes & Metabolic Disorders.2026;[Epub]     CrossRef
  • Advances in Cholesterol Regulation by Lactobacillus : Technical Approaches, Mechanisms of Action, and Potential for Clinical Translation
    Jingjing Wang, Yuxin Wang, Yangying Sun, Xiaojiao Zheng, Xiaoqun Zeng, Zhen Wu, Daodong Pan, Maolin Tu
    Food Reviews International.2026; : 1.     CrossRef
  • Lactobacillus murinus Alleviates High Fructose‐Induced MASLD by Boosting Arginine Production
    Xinglin Mo, Guilin Zhao, Lanlan Liu, Lan Zhen, Qing Huang, Yue Wang, Xiaopan Yang, Linfei Huang, Luming Wan, Congwen Wei, Ruzhou Zhao, Jie Hu, Yong Li, Jing Yuan, Chenke Ma, Feixiang Wu
    Food Science & Nutrition.2026;[Epub]     CrossRef
  • Lacticaseibacillus rhamnosus B6 alleviates metabolic dysfunction-associated fatty liver disease by suppressing intestinal LPS synthesis and regulating lipid metabolism
    Danqi Wang, Jin Han, Xiaohua Wang, Jing Wang, Chunping You, Zhengjun Wu
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Long-term systemic effects of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/MAFLD) in children: a systematic review of persistence and progression into adulthood
    Beatriz Rey-Garcia, Maria Teresa Reyes-Chacon, Eduardo Rosas-Blum, Marie Leiner
    Annals of Hepatology.2026; 31(1): 102197.     CrossRef
  • Hepatoprotective effect of administering a probiotic strain (Lactobacillus acidophilus) to mice when consuming sucrose
    Marco Soria-Mamani, Oscar Gustavo Huaman Gutierrez
    Nutrire.2026;[Epub]     CrossRef
  • Pathogenesis of fatty liver haemorrhagic syndrome in laying hens and advances in nutritional intervention through feed additives
    Lanlan Li, Jie Gao, Xin Wang, Yujiao Lai, Zhengfan Zhang, Shuangshuang Guo, Binying Ding
    World's Poultry Science Journal.2026; : 1.     CrossRef
  • MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues
    Suki Ha, Xiang Zhang, Lanjuan Li, Jun Yu
    Science Bulletin.2026;[Epub]     CrossRef
  • Diabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies
    Bhumika Munda, Chimila Bhutia, Deepti, Manisha Khatri
    Letters in Applied NanoBioScience.2026;[Epub]     CrossRef
  • Obesity, type 2 diabetes, and the gut microbiome: A case-control investigation of L. acidophilus, L. rhamnosus, and B. bifidum
    Niloofar Sadooghi, Amir Mohammad Salimi Sharif, Soheil Rahmani Fard, Somayeh Soleymanzadeh Moghadam, Sara Minaeian
    Endocrine and Metabolic Science.2026; 21: 100308.     CrossRef
  • Multistrain Probiotics Alleviate Diarrhea by Modulating Microbiome-Derived Metabolites and Serotonin Pathway
    Jin-Ju Jeong, Yoo-Jeong Jin, Raja Ganesan, Hee Jin Park, Byeong Hyun Min, Min Kyo Jeong, Sang Jun Yoon, Mi Ran Choi, Satya Priya Sharma, You Jin Jang, Uigi Min, Jong-Hyun Lim, Kyeong Min Na, Jieun Choi, Sang Hak Han, Young Lim Ham, Do Yup Lee, Byung-Yong
    Probiotics and Antimicrobial Proteins.2025; 17(5): 2894.     CrossRef
  • Comparative effects of viable Lactobacillus rhamnosus GG and its heat‐inactivated paraprobiotic in the prevention of high‐fat high‐fructose diet‐induced non‐alcoholic fatty liver disease in rats
    Laura Isabel Arellano‐García, Iñaki Milton‐Laskibar, J. Alfredo Martínez, Miguel Arán‐González, María P. Portillo
    BioFactors.2025;[Epub]     CrossRef
  • Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction‐associated steatotic liver disease: a comprehensive review
    Jie‐Lun Ku, Jia‐Rou Hsu, Yung‐Tsung Li, Li‐Ling Wu
    Journal of Gastroenterology and Hepatology.2025; 40(1): 33.     CrossRef
  • The Role of the Gut Microbiome in the Development and Progression of Type 2 Diabetes and Liver Disease
    Asha Guraka, Sreejesh Sreedharan, Ramesh Arasaradnam, Gyan Tripathi, Ali Kermanizadeh
    Nutrition Reviews.2025; 83(7): e2025.     CrossRef
  • Research hotspots and trends in gut microbiota and nonalcoholic fatty liver disease: A bibliometric study
    Cai-Yun Huang, Zhong-Zhi Luo, Wei-Ping Huang, Li-Ping Lin, You-Ting Yao, Han-Xu Zhuang, Qiu-Yong Xu, Ya-Dong Lai
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Gut microbiota: A new key of understanding for Panax notoginseng against multiple disorders and biotransformation
    Yueting Mo, Xiyuan He, Hao Cui, Yifan Cheng, Mingmei Zhou, Xiuming Cui, Ting Zhang
    Journal of Ethnopharmacology.2025; 341: 119306.     CrossRef
  • Microbiota Co-Metabolism Alterations Precede Changes in the Host Metabolism in the Early Stages of Diet-Induced MASLD in Wistar Rats
    María Martín-Grau, Pilar Casanova, Laura Moreno-Morcillo, José Manuel Morales, Vannina G. Marrachelli, Daniel Monleón
    International Journal of Molecular Sciences.2025; 26(3): 1288.     CrossRef
  • Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
    Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo
    International Journal of Molecular Sciences.2025; 26(4): 1778.     CrossRef
  • Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease
    Sang Yoon Lee, Su-Been Lee, Goo-Hyun Kwon, Seol Hee Song, Jeong Ha Park, Min Ju Kim, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Satya Priya Sharma, Ki Tae
    Journal of Microbiology.2025; 63(2): e2411002.     CrossRef
  • JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut–liver axis and lipid metabolism
    Wenying Qi, Xu Cao, Yue Chen, Hening Chen, Ningyi Zhang, Ruijia Liu, Wei Wang, Qiyao Liu, Shihao Zheng, Size Li, Xiaoke Li, Xiaobin Zao, Yong'an Ye
    Phytomedicine.2025; 140: 156559.     CrossRef
  • Benefits of inulin and fructo-oligosaccharides on high fat diet-induced type 2 diabetes mellitus by regulating the gut microbiota in mice
    Xiaoqin Ding, Yan Chen, Lanlan Du, Jing Li, Xiuhua Meng, Han Lv, Bei Tong, Guanting Niu, Tunyu Jian, Jian Chen
    The Journal of Nutritional Biochemistry.2025; 141: 109908.     CrossRef
  • Administration of a probiotic supplement attenuates nonalcoholic fatty liver disease by reducing hepatic lipid accumulation, oxidative stress, and inflammation
    Pennapa CHONPATHOMPIKUNLERT, Pratoomporn YINGTHONGCHAI, Suriya TATEING, Anuwat AMATACHAYA, Sasalux KAEWBUTRA, Neungnut CHAIYAWAN, Thanyarat LEKCHAOUM, Chaivarakun CHAIPANYA, Wachirawadee MALAKUL, Jurairat KHONGRUM
    Bioscience of Microbiota, Food and Health.2025; 44(2): 160.     CrossRef
  • Integrating microbial GWAS and single-cell transcriptomics reveals associations between host cell populations and the gut microbiome
    Jingjing Li, Yunlong Ma, Yue Cao, Gongwei Zheng, Qing Ren, Cheng Chen, Qunyan Zhu, Yijun Zhou, Yu Lu, Yaru Zhang, Chunyu Deng, Wei-Hua Chen, Jianzhong Su
    Nature Microbiology.2025; 10(5): 1210.     CrossRef
  • Harnessing lactobacillus : a probiotic revolution in combating metabolic dysfunction-associated steatotic liver disease
    Minwen Gu, Qing Hong, Jie Cui, Wenhui Li, Jian Zhang, Ye Sun, Jinchi Jiang, Yonghong Hu
    Critical Reviews in Food Science and Nutrition.2025; 65(33): 8516.     CrossRef
  • Effects of Lactobacillus fermentum GKF3 on Reducing Smoking and Brain Neurotransmitter Levels: Findings From Animal and Human Studies
    You‐Shan Tsai, Shan Lin, Chin‐Chu Chen, Chun‐Hung Chiu, Mei‐Chin Mong, Shu‐Ling Hu, Chi‐Hao Wu
    Food Frontiers.2025; 6(4): 2065.     CrossRef
  • Exploring the mechanisms of tetrahydrocurcumin in ameliorating nonalcoholic steatohepatitis based on network pharmacology and gut microbiota analysis in vivo and in vitro
    Keyu Chen, Jianbo Wang, Shuang Luo, Yunyun Quan, Ping Wei, Jiali Fu, Jiali Ma, Yuying Yang, Yunten Liu, Zhichong Gao
    Frontiers in Microbiology.2025;[Epub]     CrossRef
  • The liver-gut axis perspective: Exploring the pathogenesis of fatty liver
    Zonghui Yang, Jinbao Zhang, Xiaona Liu, Honggang Chen, Haijing Duan, Qian Wang, Wenlong Zhao, Ling Jin
    European Journal of Pharmacology.2025; 1002: 177822.     CrossRef
  • Optimization of microwave-assisted extraction for quercetin (prebiotic) and the effect of its symbiotic combination with Lactobacillus acidophilus (probiotic) in NAFLD induced rat model
    Mehwish Majeed, Waqas Ahmed, Sumera Javad, Iahtisham-Ul-Haq, Summer Rashid, Rashida Perveen, Umar Farooq, Juweria Abid, Abdul Momin Rizwan Ahmad
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • The Effects of Wuniuzao Green Tea on Mice With High‐Fat Diet‐Induced Liver Steatosis
    Yiwei Yuan, Jiangcheng Ye, Mingxiu Gong, Yifan Zhang, Qianqian Xu, Jin Zhao
    Food Science & Nutrition.2025;[Epub]     CrossRef
  • Probiotics as a therapeutic strategy for metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis
    Jing Lu, Xiaoxiao Dong, Ziqi Gao, Huizhen Yan, Dilireba Shataer, Liang Wang, Yanan Qin, Minwei Zhang, Jiayi Wang, Jie Cui, Shengyang Zhou
    Current Research in Food Science.2025; 11: 101138.     CrossRef
  • Gastrointestinal Microbial Involvement in Gallstone Formation: A Systematic Review
    Sirui Wan, Kun Xia, Yunpeng Liu, Hongzhi Xu
    Health and Metabolism.2025; : 3.     CrossRef
  • Cistanche tubulosa glycosides ameliorate cognitive decline in APP/PS1 mice via modulation of gut microbiota and fatty acid metabolism: insights from multi-omics and experimental validation
    Rui Hou, Wei Song, Yi Nan, Yiyi Gong, Jieying Liu, Jialin Liu
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • MicrobiomeKG: bridging microbiome research and host health through knowledge graphs
    Skye L. Goetz, Amy K. Glen, Gwênlyn Glusman
    Frontiers in Systems Biology.2025;[Epub]     CrossRef
  • Changes in viable cell counts and functional properties of lactic acid bacteria products under simulated marine shipping conditions
    Se-Won Lee, Joong Sang Cho, Jeong-Muk Lim, Do-Yoeon Jang, Jun Hur, Jun Jae Jung, Byung-Taek Oh
    Food Science and Preservation.2025; 32(4): 603.     CrossRef
  • Stachyose Attenuates Hepatic Cholesterol Deposition in Nonalcoholic Fatty Liver Mice via Gut Microbiota-Driven Bile Acid Profile Remodeling
    Yanqi Li, Ying Fan, Yashi Zhang, Aizhen Zong, Fangling Du, Tongcheng Xu
    Journal of Agricultural and Food Chemistry.2025; 73(41): 26130.     CrossRef
  • Akkermansia muciniphila: a microbial guardian against oxidative stress–gut microbiota crosstalk and clinical prospects
    Wen-Yu Ye, Yan Cai
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • The Gut Health Revolution: Herbs and Dietary Phytochemicals in Balancing Gut Microbiota for Optimal Human Health
    Afeefa Khan, Sageer Abass, Syed Ali Imam Nizami, Mohd Shariq, Sultan Zahiruddin, Bushra Parveen, Rabea Parveen
    Current Pharmaceutical Biotechnology.2025; 26(14): 2339.     CrossRef
  • Revealing the Causal Relationship of the Gut‐Liver Axis in MASH: A Study Based on Mendelian Randomization and Multi‐Omics
    Dapeng Yin, Jiacheng Cheng, Huili Cao, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li
    The FASEB Journal.2025;[Epub]     CrossRef
  • Lactobacillus gasseri TF08-1 ameliorates high-fat diet induced nonalcoholic fatty liver disease and regulates gut microbiota in mice
    Qianyue Xu, Ningning He, Yu Tian, Zhinan Wu, Haoyu Wang, Bei Liu, Zizhen Yang, Haifeng Zhang, Qiang Luo, Yiyi Zhong, Liang Xiao, Shangyong Li, Yuanqiang Zou
    Journal of Applied Microbiology.2025;[Epub]     CrossRef
  • The Dual Role of Gut Microbiota and Their Metabolites in Hepatocellular Carcinoma: A Context-Dependent Framework
    Shuyu Zuo, Junhui Ma, Xue Li, Zhengyang Fan, Xiao Li, Yingen Luo, Lei Su
    Microorganisms.2025; 14(1): 73.     CrossRef
  • Changes in viable cell counts and functional properties of lactic acid bacteria products under simulated marine shipping conditions
    Se-Won Lee, Joong Sang Cho, Jeong-Muk Lim, Do-Yoeon Jang, Jun Hur, Jun Jae Jung, Byung-Taek Oh
    Food Science and Preservation.2025; 32(4): 603.     CrossRef
  • Pien Tze Huang Protects Against Non-Alcoholic Steatohepatitis by Modulating the Gut Microbiota and Metabolites in Mice
    Xianyi Zeng, Xiang Zhang, Hao Su, Hongyan Gou, Harry Cheuk-Hay Lau, Xiaoxu Hu, Ziheng Huang, Yan Li, Jun Yu
    Engineering.2024; 35: 257.     CrossRef
  • The Effect of Heat-Killed Lactobacillus plantarum on Oxidative Stress and Liver Damage in Rats with Bile Duct Ligation-Induced Hepatic Fibrosis
    Shima Kabiri-Arani, Mitra Motallebi, Maryam Akhavan Taheri, Nejat Kheiripour, Abolfazl Ardjmand, Esmat Aghadavod, Mohammad Esmaeil Shahaboddin
    Probiotics and Antimicrobial Proteins.2024; 16(1): 196.     CrossRef
  • Composition of gut microbiota and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
    Xin Su, Shiyun Chen, Jiazi Liu, Yonghui Feng, Eerdun Han, Xiaolei Hao, Minqi Liao, Jun Cai, Shiwen Zhang, Jianxiang Niu, Shihua He, Shaofen Huang, Kenneth Lo, Fangfang Zeng
    Obesity Reviews.2024;[Epub]     CrossRef
  • Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid
    Harry Cheuk-Hay Lau, Xiang Zhang, Fenfen Ji, Yufeng Lin, Wei Liang, Qing Li, Danyu Chen, Winnie Fong, Xing Kang, Weixin Liu, Eagle Siu-Hong Chu, Queena Wing-Yin Ng, Jun Yu
    eBioMedicine.2024; 100: 104952.     CrossRef
  • Polysaccharide from Panax japonicus C.A. Mey prevents non-alcoholic fatty liver disease development based on regulating liver metabolism and gut microbiota in mice
    Yi Wu, Wen Yin, Ping Hao, Yueru Chen, Lingyun Yu, Xingjian Yu, Yu Wu, Xiaocong Li, Wenjia Wang, Hui Zhou, Yuan Yuan, Xiaoyu Quan, Yue Yu, Bing Hu, Shouhai Chen, Zhenlei Zhou, Wenjing Sun
    International Journal of Biological Macromolecules.2024; 260: 129430.     CrossRef
  • Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
    Wasitha P. D. W. Thilakarathna, H. P. Vasantha Rupasinghe
    Molecules.2024; 29(3): 709.     CrossRef
  • Effects of selenium nanoparticles produced by Lactobacillus acidophilus HN23 on lipid deposition in WRL68 cells
    Xianglan Lei, Yuxuan Peng, Yan Li, Qianyuan Chen, Zhenguo Shen, Wen Yin, Viktar Lemiasheuski, Siyang Xu, Jin He
    Bioorganic Chemistry.2024; 145: 107165.     CrossRef
  • Effects of dietary supplementation of fish oil plus vitamin D3 on gut microbiota and fecal metabolites, and their correlation with nonalcoholic fatty liver disease risk factors: a randomized controlled trial
    Xueqi Li, Chi Pan, Wenjun Ma, Ting Yang, Chong Wang, Weiwei Han, Wei Zhang, Hui Li, Zhongxia Li, Ting Zhao, Xiao-fei Guo, Duo Li
    Food & Function.2024; 15(5): 2616.     CrossRef
  • New aspects characterizing non-obese NAFLD by the analysis of the intestinal flora and metabolites using a mouse model
    Wenji Zhang, Wenli Cheng, JingHui Li, Zhenrui Huang, Hui Lin, Wenjuan Zhang, Rosie Alegado
    mSystems.2024;[Epub]     CrossRef
  • Differences among Lactiplantibacillus plantarum strains isolated from different fermented foods in their potential cholesterol-lowering properties
    Shu-Jun Guo, Chang-Cheng Li, Yu-Ting Feng, Yan-Ru Zhou, Bin Liu, Zhen-Peng Gao, Chun-Feng Guo
    Food Bioscience.2024; 59: 103847.     CrossRef
  • Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023)
    Xiaofei Zhu, Ziyuan Zhou, Xiaxia Pan
    Frontiers in Microbiology.2024;[Epub]     CrossRef
  • Semaglutide alters gut microbiota and improves NAFLD in db/db mice
    Tuohua Mao, Chenxuan Zhang, Shuang Yang, Yingying Bi, Man Li, Jia Yu
    Biochemical and Biophysical Research Communications.2024; 710: 149882.     CrossRef
  • Bacterial Community Influences the Effects of Lactobacillus acidophilus on Lipid Metabolism, Immune Response, and Antioxidant Capacity in Dogs
    Aipeng Mao, Xiaoli Chen, Weigang Zhao, Weixiao Nan, Yao Huang, Yalong Sun, Haihua Zhang, Chao Xu
    Animals.2024; 14(9): 1257.     CrossRef
  • Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
    Aakash Mantri, Anika Köhlmoos, Daniela Stephanie Schelski, Waldemar Seel, Birgit Stoffel-Wagner, Peter Krawitz, Peter Stehle, Jens Juul Holst, Bernd Weber, Leonie Koban, Hilke Plassmann, Marie-Christine Simon
    Nutrients.2024; 16(9): 1300.     CrossRef
  • Therapeutic potential of Lactobacillus casei and Chlorella vulgaris in high-fat diet-induced non-alcoholic fatty liver disease (NAFLD)-associated kidney damages: a stereological study
    Haniyeh Keyghobadi, Hadis bozorgpoursavadjani, Farhad Koohpeyma, Nazanin Mohammadipoor, Marzieh Nemati, Farshad Dehghani, Iman Jamhiri, Gholamhossein Keighobadi, Sanaz Dastghaib
    Molecular Biology Reports.2024;[Epub]     CrossRef
  • Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
    Nicolás Ortiz-López, Ana María Madrid, Larissa Aleman, Alejandra Zazueta, Gladys Smok, Lucía Valenzuela-Pérez, Jaime Poniachik, Caroll J. Beltrán
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options
    Natalia G. Vallianou, Dimitris Kounatidis, Sotiria Psallida, Nikolaos Vythoulkas-Biotis, Andreas Adamou, Tatiana Zachariadou, Sofia Kargioti, Irene Karampela, Maria Dalamaga
    Metabolites.2024; 14(7): 366.     CrossRef
  • Integrated serum metabolomics, 16S rRNA sequencing and bile acid profiling to reveal the potential mechanism of gentiopicroside against nonalcoholic steatohepatitis in lean mice
    Zeyun Li, Xueya Zhu, Chenhao Li, Ruiting Tang, Yuanyuan Zou, Shuaibing Liu
    Journal of Ethnopharmacology.2024; 334: 118526.     CrossRef
  • Vinpocetine and Lactobacillus improve fatty liver in rats: role of adiponectin and gut microbiome
    Ahmed M. El-Baz, Ahmed Shata, Nehal A. Nouh, Lubna Jamil, Mohamed M. Hafez, Sally Negm, Attalla F. El-kott, Mohammed A. AlShehri, Eman M. Khalaf
    AMB Express.2024;[Epub]     CrossRef
  • Physiological Effects of Lactic Acid Bacteria on Induced Non-Alcoholic Fatty Liver Disease in Male Laboratory Rats
    Mohammed F. Ayyed, Feryal F. Hussein, Mohammed J. Mohammed
    IOP Conference Series: Earth and Environmental Science.2024; 1371(6): 062019.     CrossRef
  • Impact of Lactobacillaceae supplementation on the multi-organ axis during MASLD
    André A. Santos, Raquel Duarte, Madalena Duarte, Fabiola Arella, Vanda Marques, Stefan Roos, Cecília M.P. Rodrigues
    Life Sciences.2024; 354: 122948.     CrossRef
  • Gut Microbiome and Metabolome Alterations in Overweight or Obese Adult Population after Weight-Loss Bifidobacterium breve BBr60 Intervention: A Randomized Controlled Trial
    Zhouya Bai, Ying Wu, Dejiao Gao, Yao Dong, Yujia Pan, Shaobin Gu
    International Journal of Molecular Sciences.2024; 25(20): 10871.     CrossRef
  • The influence of perilipin 5 deficiency on gut microbiome profiles in murine metabolic dysfunction-associated fatty liver disease (MAFLD) and MAFLD-hepatocellular carcinoma
    Marinela Krizanac, Paula Štancl, Paola Berenice Mass-Sanchez, Rosa Karlić, Diana Moeckel, Twan Lammers, Anastasia Asimakopoulos, Ralf Weiskirchen
    Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
  • Association between hepatocyte TM4SF5 expression and gut microbiome dysbiosis during non-alcoholic fatty liver disease development
    Yangie Dwi Pinanga, Kyung-hee Pyo, Eun-Ae Shin, Haesong Lee, Eun Hae Lee, Wonsik Kim, Soyeon Kim, Ji Eon Kim, Semi Kim, Jung Weon Lee
    Life Sciences.2024; 358: 123164.     CrossRef
  • Copper oxide nanoparticles induce non-alcoholic fatty liver disease by disrupting bile acid homeostasis and perturbing the intestinal microbial homeostasis
    Muran Jiang, Xiaoqi Tao, Yingxin Pang, Zongmin Qin, Erqun Song, Yang Song
    Journal of Hazardous Materials.2024; 480: 136416.     CrossRef
  • Timing Matters: Late, but Not Early, Exercise Training Ameliorates MASLD in Part by Modulating the Gut‐Liver Axis in Mice
    Artemiy Kovynev, Zhixiong Ying, Sen Zhang, Emanuele Olgiati, Joost M. Lambooij, Clara Visentin, Bruno Guigas, Quinten R. Ducarmon, Patrick C. N. Rensen, Milena Schönke
    Journal of Pineal Research.2024;[Epub]     CrossRef
  • The probiotic Lacticaseibacillus rhamnosus SD11 alleviates the progression of liver and colon damage through modulation of inflammation and tight junction proteins in streptozotocin-induced diabetic mice
    Waraporn Ruathong, Pissared Khuituan, Saranya Peerakietkhajorn, Rawee Teanpaisan, Jongdee Nopparat, Sayed Haidar Abbas Raza
    PLOS ONE.2024; 19(11): e0313395.     CrossRef
  • Gut ecological networks reveal associations between bacteria, exercise, and clinical profile in non-alcoholic fatty liver disease patients
    Susanne Csader, Xiuqiang Chen, Howell Leung, Ville Männistö, Heikki Pentikäinen, Milla-Maria Tauriainen, Kai Savonen, Hani El-Nezami, Ursula Schwab, Gianni Panagiotou, Marc D. Cook
    mSystems.2023;[Epub]     CrossRef
  • Tetrastigma hemsleyanumleaf extracts ameliorate NAFLD in mice with low-grade colitisviathe gut–liver axis
    Lihua Xiao, Hua Xiong, Zeyuan Deng, Xin Peng, Kejun Cheng, Hua Zhang, Li Jiang, Yong Sun
    Food & Function.2023; 14(1): 500.     CrossRef
  • Protective Effects of Lactobacillus gasseri against High-Cholesterol Diet-Induced Fatty Liver and Regulation of Host Gene Expression Profiles
    Tianhua He, Nikita Lykov, Xu Luo, Huiling Wang, Zhanxiang Du, Ziyi Chen, Shitian Chen, Lin Zhu, Ye Zhao, Chimeng Tzeng
    International Journal of Molecular Sciences.2023; 24(3): 2053.     CrossRef
  • Dendrobium officinale alleviates high-fat diet-induced nonalcoholic steatohepatitis by modulating gut microbiota
    Gege Tian, Wei Wang, Enrui Xia, Wenhui Chen, Shunzhen Zhang
    Frontiers in Cellular and Infection Microbiology.2023;[Epub]     CrossRef
  • Effects of SCFAs and TMAO on non-alcoholic fatty liver disease indicating the therapeutic benefits of plant-based diet, and supplemental prebiotics, probiotics and synbiotics
    Vuong Vu, Young Mee Kim, Moonjae Cho
    Applied Biological Chemistry.2023;[Epub]     CrossRef
  • Limosilactobacillus fermentum MG4294 and Lactiplantibacillus plantarum MG5289 Ameliorates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Mice
    Ji Yeon Lee, Minju An, Huijin Heo, Jeong-Yong Park, Junsoo Lee, Chang-Ho Kang
    Nutrients.2023; 15(8): 2005.     CrossRef
  • Probiotics as Potential Therapy in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD)
    Margalida Monserrat-Mesquida, Cristina Bouzas, Catalina M. Mascaró, Silvia Tejada, Antoni Sureda
    Fermentation.2023; 9(4): 395.     CrossRef
  • Ameliorating effect of probiotic on nonalcoholic fatty liver disease and lipolytic gene expression in rabbits
    Marina Aziz, Shabaan A. Hemeda, Ghadeer M. Albadrani, Sabreen E. Fadl, Fatma Elgendey
    Scientific Reports.2023;[Epub]     CrossRef
  • Therapeutic mechanisms of the medicine and food homology formula Xiao-Ke-Yin on glucolipid metabolic dysfunction revealed by transcriptomics, metabolomics and microbiomics in mice
    Mei Li, Ding Cheng, Chuan Peng, Yujiao Huang, Jie Geng, Guangrui Huang, Ting Wang, Anlong Xu
    Chinese Medicine.2023;[Epub]     CrossRef
  • Supplementation of Lactobacillus plantarum ATCC14917 mitigates non-alcoholic fatty liver disease in high-fat-diet-fed rats
    Xingjian Wen, Hejing Liu, Xiaoling Luo, Li Lui, Jiuyu Fan, Yajing Xing, Jia Wang, Xingfang Qiao, Na Li, Guixue Wang
    Frontiers in Microbiology.2023;[Epub]     CrossRef
  • MicroRNA‐29a Compromises Hepatic Adiposis and Gut Dysbiosis in High Fat Diet‐Fed Mice via Downregulating Inflammation
    Ya‐Ling Yang, Ying‐Hsien Huang, Feng‐Sheng Wang, Ming‐Chao Tsai, Chien‐Hung Chen, Wei‐Shiung Lian
    Molecular Nutrition & Food Research.2023;[Epub]     CrossRef
  • Brown adipose tissue-derived Nrg4 alleviates non-alcoholic fatty liver disease in mice
    Jing Luo, Ming Chen, Hongwu Ji, Weifeng Su, Wenkui Song, Di Zhang, Weiming Su, Shucheng Liu
    Journal of Functional Foods.2023; 108: 105735.     CrossRef
  • Sanguisorba officinalis L. Ameliorates Hepatic Steatosis and Fibrosis by Modulating Oxidative Stress, Fatty Acid Oxidation, and Gut Microbiota in CDAHFD-Induced Mice
    Yunseong Nam, Myungsuk Kim, Saruul Erdenebileg, Kwang Hyun Cha, Da Hye Ryu, Ho Youn Kim, Su Hyeon Lee, Je Hyeong Jung, Chu Won Nho
    Nutrients.2023; 15(17): 3779.     CrossRef
  • The PKA‐SREBP1c Pathway Plays a Key Role in the Protective Effects of Lactobacillus johnsonii JNU3402 Against Diet‐Induced Fatty Liver in Mice
    Eunjeong Hong, Hyuno Kang, Garam Yang, Sejong Oh, Eungseok Kim
    Molecular Nutrition & Food Research.2023;[Epub]     CrossRef
  • Metagenomic signatures reveal the key role of phloretin in amelioration of gut dysbiosis attributed to metabolic dysfunction-associated fatty liver disease by time-dependent modulation of gut microbiome
    Jyoti Chhimwal, Prince Anand, Priyanka Mehta, Mohit Kumar Swarnkar, Vikram Patial, Rajesh Pandey, Yogendra Padwad
    Frontiers in Microbiology.2023;[Epub]     CrossRef
  • Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance
    Kyoung Jin Choi, Mi Young Yoon, Ji-Eun Kim, Sang Sun Yoon
    Scientific Reports.2023;[Epub]     CrossRef
  • Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating l-arginine production
    Dong Yun Kim, Jun Yong Park, Heon Yung Gee
    Experimental & Molecular Medicine.2023; 55(11): 2332.     CrossRef
  • Amlodipine, an anti‐hypertensive drug, alleviates non‐alcoholic fatty liver disease by modulating gut microbiota
    Yang Li, Danyang Zhao, Minyi Qian, Jun Liu, Chuyue Pan, Xinxin Zhang, Xubin Duan, Yufei Zhang, Wenxin Jia, Lirui Wang
    British Journal of Pharmacology.2022; 179(9): 2054.     CrossRef
  • The Lactobacillus as a Probiotic: Focusing on Liver Diseases
    Jin-Ju Jeong, Hee Jin Park, Min Gi Cha, Eunju Park, Sung-Min Won, Raja Ganesan, Haripriya Gupta, Yoseph Asmelash Gebru, Satya Priya Sharma, Su Been Lee, Goo Hyun Kwon, Min Kyo Jeong, Byeong Hyun Min, Ji Ye Hyun, Jung A Eom, Sang Jun Yoon, Mi Ran Choi, Don
    Microorganisms.2022; 10(2): 288.     CrossRef
  • Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
    Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do
    Biomedicines.2022; 10(3): 550.     CrossRef
  • Modulatory effects of phenolics extract of Costus afer leaves on cadmium induced nephrotoxicity and hepatoxicity in Wistar rats
    Tope Gafar Atere, O. O. Oladokun, O. S. Osuntokun, K. I. Adedokun, J. O. Fatoki, S. A. Olawumi, O. S. Tokunbo, O. O. Obembe, O. S. Afolabi
    Toxicology and Environmental Health Sciences.2022; 14(2): 157.     CrossRef
  • Usefulness of Probiotics in the Management of NAFLD: Evidence and Involved Mechanisms of Action from Preclinical and Human Models
    Laura Arellano-García, María P. Portillo, J. Alfredo Martínez, Iñaki Milton-Laskibar
    International Journal of Molecular Sciences.2022; 23(6): 3167.     CrossRef
  • Docosahexaenoic acid-rich fish oil alleviates hepatic steatosis in association with regulation of gut microbiome in ob/ob mice
    Mohammed Said Moose Al-Bulish, Wanxiu Cao, Ruili Yang, Yuming Wang, Changhu Xue, Qingjuan Tang
    Food Research International.2022; 157: 111373.     CrossRef
  • Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis
    Qionglian Fang, Xinping Li, Mengmeng Wang, Xue Qiao, Feng Huang, Chunyan Hu, Yongmei Xue, Shenglan Zhao, Yuping Lin
    Food & Function.2022; 13(11): 6387.     CrossRef
  • Resilience and the Gut Microbiome: Insights from Chronically Socially Stressed Wild-Type Mice
    Malena dos Santos Guilherme, Francesco Valeri, Jennifer Winter, Marianne B. Müller, Andreas Schwiertz, Kristina Endres
    Microorganisms.2022; 10(6): 1077.     CrossRef
  • The Potential Effect of Intestinal Flora and Metabolites on High-Fat Diet-Mediated Nonalcoholic Fatty Liver Disease
    志伟 韩
    Advances in Clinical Medicine.2022; 12(05): 4823.     CrossRef
  • Gut microbiota mediates methamphetamine-induced hepatic inflammation via the impairment of bile acid homeostasis
    Kai-Kai Zhang, Jia-Li Liu, Li-Jian Chen, Jia-Hao Li, Jian-Zheng Yang, Ling-Ling Xu, Yu-Kui Chen, Qin-Yao Zhang, Xiu-Wen Li, Yi Liu, Dong Zhao, Xiao-Li Xie, Qi Wang
    Food and Chemical Toxicology.2022; 166: 113208.     CrossRef
  • A Transcriptomic Response to Lactiplantibacillus plantarum-KCC48 against High-Fat Diet-Induced Fatty Liver Diseases in Mice
    Ilavenil Soundharrajan, Muthusamy Karnan, Jeong-Sung Jung, Kyung-Dong Lee, Jeong-Chae Lee, Thiyagarajan Ramesh, Dahye Kim, Ki-Choon Choi
    International Journal of Molecular Sciences.2022; 23(12): 6750.     CrossRef
  • Gut Commensal Parabacteroides goldsteinii MTS01 Alters Gut Microbiota Composition and Reduces Cholesterol to Mitigate Helicobacter pylori-Induced Pathogenesis
    Chih-Ho Lai, Tzu-Lung Lin, Mei-Zi Huang, Shiao-Wen Li, Hui-Yu Wu, Ya-Fang Chiu, Chia-Yu Yang, Cheng-Hsun Chiu, Hsin-Chih Lai
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
    Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2022; 28(3): 425.     CrossRef
  • Total Flavonoids from Chimonanthus nitens Oliv. Leaves Ameliorate HFD-Induced NAFLD by Regulating the Gut–Liver Axis in Mice
    Wenya Meng, Zitong Zhao, Lingli Chen, Suyun Lin, Yang Zhang, Jing He, Kehui Ouyang, Wenjun Wang
    Foods.2022; 11(14): 2169.     CrossRef
  • Effects of garlic and its major bioactive components on non-alcoholic fatty liver disease: A systematic review and meta-analysis of animal studies
    Sara Shojaei-Zarghani, Mohammad Reza Fattahi, Asma Kazemi, Ali Reza Safarpour
    Journal of Functional Foods.2022; 96: 105206.     CrossRef
  • Investigation of Gynura segetum root extract (GSrE) induced hepatotoxicity based on metabolomic signatures and microbial community profiling in rats
    Xinyi Gu, Shuwei Li, Mengna Lu, Ying Li, Qixue Wang, Long Chen, Yiqun Jia, Shan Cao, Ting Zhang, Mingmei Zhou, Xiaojun Gou
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
    Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang
    Signal Transduction and Targeted Therapy.2022;[Epub]     CrossRef
  • Depletion of Gut Microbiota Inhibits Hepatic Lipid Accumulation in High-Fat Diet-Fed Mice
    Hui Han, Mengyu Wang, Ruqing Zhong, Bao Yi, Martine Schroyen, Hongfu Zhang
    International Journal of Molecular Sciences.2022; 23(16): 9350.     CrossRef
  • The Functional Roles of Lactobacillus acidophilus in Different Physiological and Pathological Processes
    Huijuan Gao, Xin Li, Xiatian Chen, Deng Hai, Chuang Wei, Lei Zhang, Peifeng Li
    Journal of Microbiology and Biotechnology.2022; 32(10): 1226.     CrossRef
  • Adlay (Coix lacryma‐jobi L.) Polyphenol Improves Hepatic Glucose and Lipid Homeostasis through Regulating Intestinal Flora via AMPK Pathway
    Shengsuo Ma, Bing Yang, Yucong Shi, Yang Du, Yiwen Lv, Jiarong Liu, Enyan Liu, Huachong Xu, Li Deng, Xiao‐yin Chen
    Molecular Nutrition & Food Research.2022;[Epub]     CrossRef
  • Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice
    Fang Xie, Hang-fei Xu, Jing Zhang, Xiao-ni Liu, Bu-xin Kou, Meng-yin Cai, Jing Wu, Jin-ling Dong, Qing-hua Meng, Yi Wang, Dexi Chen, Yang Zhang
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Triglyceride: A mediator of the association between waist-to-height ratio and non-alcoholic fatty liver disease: A second analysis of a population-based study
    Haofei Hu, Yong Han, Yufei Liu, Mijie Guan, Qijun Wan
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Genetic variants associated with circulating liver injury markers in Mexican Americans, a population at risk for non-alcoholic fatty liver disease
    Caroline M. Sabotta, Suet-Ying Kwan, Lauren E. Petty, Jennifer E. Below, Aron Joon, Peng Wei, Susan P. Fisher-Hoch, Joseph B. McCormick, Laura Beretta
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives
    Yuqiu Han, Lanjuan Li, Baohong Wang
    Frontiers of Medicine.2022; 16(5): 667.     CrossRef
  • Lactobacillus Species as Probiotics: Isolation Sources and Health Benefits
    Ameera M. Al-Yami, Abeer T. Al-Mousa, Sarah A. Al-Otaibi, Ashraf Y. Khalifa
    Journal of Pure and Applied Microbiology.2022; 16(4): 2270.     CrossRef
  • Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
    Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan
    Clinical and Molecular Hepatology.2021; 27(1): 83.     CrossRef
  • Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease
    Russell R. Fling, Timothy R. Zacharewski
    International Journal of Molecular Sciences.2021; 22(22): 12431.     CrossRef
  • Mykotherapie bei Fettstoffwechselstörungen – wertvoller Beitrag von Vitalpilzen
    Dorothee Bös
    Erfahrungsheilkunde.2021; 70(05): 264.     CrossRef
  • Isolation and Purification of β-Galactosidase Enzyme From Local Lactic Acid Bacteria Isolates to Overcome The Phenomenon of Non-Degradation of Milk Lactose
    Aisha A. Juma, Amin S. Badawy, Sanad B. Mohammed
    IOP Conference Series: Earth and Environmental Science.2021; 910(1): 012075.     CrossRef
  • The probiotic effects of AB23A on high-fat-diet-induced non-alcoholic fatty liver disease in mice may be associated with suppressing the serum levels of lipopolysaccharides and branched-chain amino acids
    Fan Xia, Shijian Xiang, Zhijuan Chen, Luyao Song, Yuxin Li, Ziqiong Liao, Bingchen Ge, Benjie Zhou
    Archives of Biochemistry and Biophysics.2021; 714: 109080.     CrossRef
  • 16,491 View
  • 525 Download
  • 115 Web of Science
  • Crossref

Hepatic neoplasm

Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging
Sunyoung Lee, Seung-seob Kim, Dong ryul Chang, Hyerim Kim, Myeong-Jin Kim
Clin Mol Hepatol 2020;26(3):340-351.
Published online June 4, 2020
DOI: https://doi.org/10.3350/cmh.2020.0004
Background/Aims
This study aimed to compare the diagnostic performances of Liver Imaging Reporting and Data System (LI-RADS) 2018 and Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) 2018 criteria on magnetic resonance imaging (MRI) for the noninvasive diagnosis of hepatocellular carcinoma (HCC) in high-risk patients.
Methods
This retrospective study included 273 treatment-naïve patients (71 patients with extracellular contrast agent [ECA]-MRI and 202 patients with hepatobiliary agent [HBA]-MRI; 352 lesions including 263 HCCs) with high risk of HCC who underwent contrast-enhanced MRI between 2016 and 2017. Two readers evaluated all lesions according to the criteria of LI-RADS 2018 and KLCA-NCC 2018. The per-lesion diagnostic performances were compared using the generalized estimating equation method.
Results
On ECA-MRI, the sensitivity and specificity of LI-RADS 2018 and KLCA-NCC 2018 were not significantly different (LR-5 vs. definite HCC: 75.8% vs. 69.4%, P=0.095 and 95.8% vs. 95.8%, P>0.999; LR-5/4 vs. definite/probable HCC: 87.1% vs.83.9%, P=0.313 and 87.5% vs. 91.7%, P=0.307). On HBA-MRI, definite HCC of KLCA-NCC 2018 showed significantly higher sensitivity (79.1% vs. 68.2%, P<0.001) than LR-5 of LI-RADS 2018 without a significant difference in specificity (93.9% vs. 95.4%, P=0.314). Definite/probable HCC of KLCA-NCC 2018 had higher specificity (92.3% vs. 80.0%, P=0.003) than LR-5/4 of LI-RADS 2018. The sensitivity was lower for definite/probable HCC than for LR-5/4 without statistical significance (85.6% vs. 88.1%, P=0.057).
Conclusions
On ECA-MRI, LI-RADS 2018 and KLCA-NCC 2018 showed comparable diagnostic performances. On HBA-MRI, definite HCC of KLCA-NCC 2018 provided better sensitivity than LR-5 category of LI-RADS 2018 without compromising the specificity, while definite/probable HCC of KLCA-NCC 2018 revealed higher specificity than LR-5/4 of LI-RADS 2018 for diagnosing HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Current State of Evidence for Use of MRI in LI‐RADS
    Ameya Madhav Kulkarni, Danielle Kruse, Kelly Harper, Eric Lam, Hoda Osman, Danyaal H. Ansari, Umaseh Sivanesan, Mustafa R. Bashir, Andreu F. Costa, Matthew McInnes, Christian B. van der Pol
    Journal of Magnetic Resonance Imaging.2025; 62(3): 640.     CrossRef
  • Imaging-based diagnosis of hepatocellular carcinoma: Liver Imaging Reporting and Data System and beyond
    Maryam Haghshomar, Andrea S Kierans, Laura Kulik, Frank H Miller, Amir A Borhani
    British Journal of Radiology.2025; 98(1173): 1344.     CrossRef
  • Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
    Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
    Wei Teng, Hung-Wei Wang, Shi-Ming Lin
    Liver Cancer.2024; 13(5): 468.     CrossRef
  • Comparison of Four Diagnostic Guidelines for Hepatocellular Carcinoma Using Gadoxetic Acid–enhanced Liver MRI
    Jeong Hee Yoon, Young Kon Kim, Jeong Woo Kim, Won Chang, Joon-Il Choi, Beom Jin Park, Jin-Young Choi, Seung-seob Kim, Hee Sun Park, Eun Sun Lee, Jeong-Sik Yu, Seong Jin Park, Myung-Won You, Chang Hee Lee, Jeong Min Lee
    Radiology.2024;[Epub]     CrossRef
  • Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
    Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
    Yonsei Medical Journal.2024; 65(7): 371.     CrossRef
  • Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis
    Sunyoung Lee, Yeun-Yoon Kim, Jaeseung Shin, Hyejung Shin, Claude B. Sirlin, Victoria Chernyak
    European Radiology.2024; 34(11): 7025.     CrossRef
  • Re-assessing the diagnostic value of the enhancing capsule in hepatocellular carcinoma imaging
    Jae Seok Bae, Jeong Min Lee, Bo Yun Hur, Jeongin Yoo, Sae-Jin Park
    Journal of Liver Cancer.2024; 24(2): 206.     CrossRef
  • Efficacy of LR-5 and LR-4/5 by Liver Imaging Reporting and Data System (MRI) for hepatocellular carcinoma: A meta-analysis
    Hongyu Jin, Jiwei Huang, Man Zhang, Yujia Yang, Hao Huang, Xuping Feng, Boyu Long, Libin Huang, Yong Zeng
    Asian Journal of Surgery.2023; 46(1): 82.     CrossRef
  • Deep Learning-Based Automatic Detection and Grading of Motion-Related Artifacts on Gadoxetic Acid-Enhanced Liver MRI
    Taeyong Park, Dong Wook Kim, Sang Hyun Choi, Seungwoo Khang, Jimi Huh, Seung Baek Hong, Tae Young Lee, Yousun Ko, Kyung Won Kim, Seung Soo Lee
    Investigative Radiology.2023; 58(2): 166.     CrossRef
  • Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS
    Se Jin Choi, Sang Hyun Choi, Dong Wook Kim, Minha Kwag, Jae Ho Byun, Hyung Jin Won, Yong Moon Shin
    Journal of Hepatology.2023; 78(3): 596.     CrossRef
  • Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
    Young Eun Chon, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do young Kim, Seong Gyu Hwang, Hong Jae Chon, Beom Kyung Kim
    Cancer Medicine.2023; 12(3): 2731.     CrossRef
  • ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis
    Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Won Young Tak, Young-Oh Kweon, Soo Young Park, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2023; 21(9): 2278.     CrossRef
  • CT/MRI Liver Imaging Reporting and Data System (LI-RADS): Standardization, Evidence, and Future Direction
    Yeun-Yoon Kim, Jin-Young Choi
    Journal of the Korean Society of Radiology.2023; 84(1): 15.     CrossRef
  • Prognosis of Primary Liver Cancer Based on LI-RADS Classification with Extracellular Agent-Enhanced MRI
    Yubo Li, Xiaoyan Ni, Xinai Liu, Chun Yang, Yi Wang, Xin Lu, Changwu Zhou
    Journal of Hepatocellular Carcinoma.2023; Volume 10: 399.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
    Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi
    Clinical and Molecular Hepatology.2023; 29(2): 197.     CrossRef
  • LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium–enhanced magnetic resonance imaging
    Hyeon Ji Jang, Sang Hyun Choi, Se Jin Choi, Won-Mook Choi, Jae Ho Byun, Hyung Jin Won, Yong Moon Shin
    European Radiology.2023; 33(8): 5792.     CrossRef
  • Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
    Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
    Hepatology.2023; 77(5): 1746.     CrossRef
  • What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
    Min Kyung Park, Yoon Jun Kim
    Clinical and Molecular Hepatology.2023; 29(2): 332.     CrossRef
  • Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(2): 252.     CrossRef
  • Diagnostic Performance of LI-RADS v2018 versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging with Hepatobiliary Agent: A Systematic Review and Meta-Analysis of Comparative Studies
    Jaeseung Shin, Sunyoung Lee, Ja Kyung Yoon, Won Jeong Son, Yun Ho Roh, Yong Eun Chung, Jin-Young Choi, Mi-Suk Park
    Gut and Liver.2023; 17(3): 466.     CrossRef
  • Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis
    David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2023; 38(8): 1372.     CrossRef
  • Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using the Korean Liver Cancer Association–National Cancer Center 2022 Criteria
    Ja Kyung Yoon, Dai Hoon Han, Sunyoung Lee, Jin-Young Choi, Gi Hong Choi, Do Young Kim, Myeong-Jin Kim
    Cancer Research and Treatment.2023; 55(3): 939.     CrossRef
  • A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoxetic Acid‐Enhanced MRI Features
    Shin Hye Hwang, Seung Baek Hong, Kyunghwa Han, Nieun Seo, Jin‐Young Choi, Jei Hee Lee, Sumi Park, Young‐Suk Lim, Do Young Kim, So Yeon Kim, Mi‐Suk Park
    Journal of Magnetic Resonance Imaging.2022; 55(6): 1877.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis
    Seunghwan Shin, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Diagnostics.2022; 12(2): 441.     CrossRef
  • Impact of the Liver Imaging Reporting and Data System on Research Studies of Diagnosing Hepatocellular Carcinoma Using MRI
    Yura Ahn, Sang Hyun Choi, Jong Keon Jang, So Yeon Kim, Ju Hyun Shim, Seung Soo Lee, Jae Ho Byun
    Korean Journal of Radiology.2022; 23(5): 529.     CrossRef
  • Fibrotic burden during antiviral therapy for chronic hepatitis B, not ALT level, independently predicts liver cancer risk
    David Sooik Kim, Beom Kyung Kim, Yeon Seok Seo, Byung Seok Kim, Byoung Kuk Jang, Sang Gyune Kim, Ki Tae Suk, Jin‐Woo Lee, Soung Won Jeong, Seung Up Kim
    Liver International.2022; 42(8): 1902.     CrossRef
  • Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting
    Cher Heng Tan, Shu-cheng Chou, Nakarin Inmutto, Ke Ma, RuoFan Sheng, YingHong Shi, Zhongguo Zhou, Akira Yamada, Ryosuke Tateishi
    Korean Journal of Radiology.2022; 23(7): 697.     CrossRef
  • Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging
    Yeun-Yoon Kim, Ji Hye Min, Jeong Ah Hwang, Woo Kyoung Jeong, Dong Hyun Sinn, Hyo Keun Lim
    Ultrasonography.2022; 41(3): 519.     CrossRef
  • Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid–enhanced MRI
    Minha Kwag, Sang Hyun Choi, Se Jin Choi, Jae Ho Byun, Hyung Jin Won, Yong Moon Shin
    Radiology.2022; 305(3): 614.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid–enhanced MRI in at-risk patients
    So Hyun Park, Young Sup Shim, Bohyun Kim, So Yeon Kim, Yun Soo Kim, Jimi Huh, Ji Hyun Park, Kyung Won Kim, Seung Soo Lee
    European Radiology.2021; 31(7): 4751.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • LI‐RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis
    Jaeseung Shin, Sunyoung Lee, Ja Kyung Yoon, Yong Eun Chung, Jin‐Young Choi, Mi‐Suk Park
    Journal of Magnetic Resonance Imaging.2021; 54(2): 518.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?
    Jae Hyon Park, Yong Eun Chung, Nieun Seo, Jin-Young Choi, Mi-Suk Park, Myeong-Jin Kim
    Korean Journal of Radiology.2021; 22(10): 1628.     CrossRef
  • Diagnostic Performance of KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis
    Dong Hwan Kim, Bohyun Kim, Seo Yeon Youn, Hokun Kim, Joon-Il Choi
    Diagnostics.2021; 11(10): 1763.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer
    Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro
    Translational Oncology.2021; 14(9): 101158.     CrossRef
  • Sonazoid-enhanced ultrasonography: comparison with CT/MRI Liver Imaging Reporting and Data System in patients with suspected hepatocellular carcinoma
    Jeong Ah Hwang, Woo Kyoung Jeong, Ji Hye Min, Yeun-Yoon Kim, Nam Hun Heo, Hyo Keun Lim
    Ultrasonography.2021; 40(4): 486.     CrossRef
  • Accuracy of Various Forms of Contrast-Enhanced MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Chun Zhao, Hongyan Dai, Juwei Shao, Qian He, Wei Su, Peng Wang, Qiuyue Tang, Junren Zeng, Song Xu, Juanjuan Zhao, Shutian Xiang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?
    So Yeon Kim
    Clinical and Molecular Hepatology.2020; 26(3): 309.     CrossRef
  • Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study
    Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Gi Soo Youn, Tae Suk Kim, Baek Gyu Jun, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi, Ki Tae Suk
    Cancers.2020; 12(11): 3347.     CrossRef
  • 13,517 View
  • 234 Download
  • 49 Web of Science
  • Crossref

Viral hepatitis

Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them
Kwang Il Seo, Si Hyun Bae, Pil Soo Sung, Chung-Hwa Park, Hae Lim Lee, Hee Yeon Kim, Hye Ji Kim, Bo Hyun Jang, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi, In-Yang Park, Juyoung Lee, Hyun Seung Lee, Sa-Jin Kim, Jung Hyun Kwon, U Im Chang, Chang Wook Kim, Se Hyun Jo, Young Lee, Fisseha Tekle, Jong-Hyun Kim
Clin Mol Hepatol 2018;24(4):374-383.
Published online June 26, 2018
DOI: https://doi.org/10.3350/cmh.2017.0082
Background/Aims
There have been numerous efforts to reduce mother-to-child transmission (MTCT) of hepatitis B virus (HBV) with antiviral agents during pregnancy. However, there are limited data regarding the outcomes of pregnant women after delivery. This study was performed to evaluate the efficacy of antiviral agents in preventing MTCT of HBV and maternal long-term outcomes.
Methods
The HBV-infected pregnant women treated with antiviral agents to prevent MTCT were retrospectively reviewed. Forty-one pregnant women who received telbivudine or tenofovir during late pregnancy (28-34 week) were analyzed. Hepatitis B virus surface antibody (HBsAb) positivity was tested in 43 infants after 7 months of birth. Eleven mothers were followed >1 year after delivery.
Results
The mean HBV DNA titer before antiviral therapy was 8.67 (6.60–9.49) log copies/mL, and the median age at delivery was 32 years (range, 22–40). Eleven patients were treated with tenofovir and 30 with telbivudine. The median duration was 57 days (range, 23–100), and the median HBV DNA titer at birth was 5.06 log copies/mL (range, 2.06–6.50). Antiviral treatments were associated with significant HBV DNA reduction (P<0.001). Among 43 infants (two cases of twins), HBsAb was not detected in two, subsequently confirmed to have HBV infection. Biochemical flare was observed in two of 11 mothers followed >12 months, and an antiviral agent was administered.
Conclusions
Antiviral treatment during late pregnancy effectively reduced MTCT. Long-term follow-up should be required in such cases. In addition, given that maternal biochemical flare occurred in 18% of mothers, re-administration of antiviral agents might be required.
  • 12,718 View
  • 340 Download
  • 1 Web of Science

Case Report

Viral hepatitis

Adefovir-induced Fanconi syndrome associated with osteomalacia
Samel Park, Woo-Il Kim, Dai-Hyun Cho, Yeo-Joo Kim, Hong-Soo Kim, Ji-Hee Kim, Seung-Kuy Cha, Kyu-Sang Park, Ji-Hye Lee, Sang Mi Lee, Eun Young Lee
Clin Mol Hepatol 2018;24(3):339-344.
Published online September 1, 2017
DOI: https://doi.org/10.3350/cmh.2017.0009
Fanconi syndrome is a dysfunction of the proximal renal tubules that results in impaired reabsorption and increased urinary loss of phosphate and other solutes. The pathophysiology of drug-induced Fanconi syndrome is unclear. Here we report the case of a 36-year-old woman who presented with pain in multiple bones and proteinuria. She had a 7-year history of taking adefovir at 10 mg/day for chronic hepatitis B. Three years previously she had received surgery for a nontraumatic right femur neck fracture, after which she continued to complain of pain in multiple bones, and proteinuria, glycosuria, and phosphaturia were noted. The findings of a light-microscope examination of a renal biopsy sample were normal, but mitochondrial damage of the proximal tubules was evident in electron microscopy. Western blot analysis revealed that the level of serum fibroblast growth factor 23 (FGF23) was lower than in normal controls. After 2 months of treatment, hypophosphatemia and proximal tubular dysfunction were reversed, and serum FGF23 had normalized. This case suggests that direct mitochondrial damage in proximal tubules can cause drug-induced Fanconi syndrome associated with osteomalacia.

Citations

Citations to this article as recorded by  Crossref logo
  • Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects
    Marcela Krečmerová, Pavel Majer, Rana Rais, Barbara S. Slusher
    Frontiers in Chemistry.2022;[Epub]     CrossRef
  • The genetic polymorphisms of XPR1 and SCL34A3 are associated with Fanconi syndrome in Chinese patients of tumor-induced osteomalacia
    Y. Jiang, X. Li, J. Feng, M. Li, O. Wang, X.-P. Xing, W.-B. Xia
    Journal of Endocrinological Investigation.2021; 44(4): 773.     CrossRef
  • Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report
    Qian Xiang, Zhiyan Liu, Yanyan Yu, Hanxu Zhang, Qiufen Xie, Guangyan Mu, Jianhua Zhang, Xinan Cen, Yimin Cui
    BMC Pharmacology and Toxicology.2020;[Epub]     CrossRef
  • Fanconi syndrome induced by adefovir dipivoxil: a case report and clinical review
    Kaixin Song, Qi Yan, Yi Yang, Mengyue Lv, Yuting Chen, Yue Dai, Le Zhang, Yi Huang, Cuntai Zhang, Hongyu Gao
    Journal of International Medical Research.2020;[Epub]     CrossRef
  • Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency
    Ryo Koda, Masafumi Tsuchida, Noriaki Iino, Ichiei Narita
    Internal Medicine.2019; 58(6): 821.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
  • Adefovir

    Reactions Weekly.2019; 1761(1): 20.     CrossRef
  • 22,173 View
  • 350 Download
  • 10 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

A lexicon for hepatocellular carcinoma surveillance ultrasonography: benign versus malignant lesions
Chansik An, Gulbahor Rakhmonova, Kyunghwa Han, Nieun Seo, Jin Young Lee, Myeong-Jin Kim, Mi-Suk Park
Clin Mol Hepatol 2017;23(1):57-65.
Published online March 24, 2017
DOI: https://doi.org/10.3350/cmh.2016.0041
Background/Aims
To suggest a lexicon for liver ultrasonography and to identify radiologic features indicative of benign or malignant lesions on surveillance ultrasonography.
Methods
This retrospective study included 188 nodules (benign, 101; malignant, 87) from 175 at-risk patients identified during surveillance ultrasonography for hepatocellular carcinoma. We created a lexicon for liver ultrasonography by reviewing relevant literature regarding the ultrasonographic features of hepatic lesions. Using this lexicon, two abdominal radiologists determined the presence or absence of each ultrasonographic feature for the included hepatic lesions. Independent factors associated with malignancy and interobserver agreement were determined by logistic regression analysis and kappa statistics, respectively.
Results
Larger tumor size (odds ratio [OR], 1.12; 95% confidence interval [CI], 1.06-1.183; P<0.001), multinodular confluent morphology (OR, 7.712; 95% CI, 1.053-56.465; P=0.044), thick hypoechoic rim (OR, 5.878; 95% CI, 2.681-12.888; P<0.001), and posterior acoustic enhancement (OR, 3.077; 95% CI, 1.237-7.655; P=0.016) were independently associated with malignant lesions. In a subgroup analysis of lesions <2 cm, none of the ultrasonographic features were significantly associated with malignancy or benignity. Interobserver agreement for morphology was fair (κ=0.36), while those for rim (κ=0.427), echogenicity (κ=0.549), and posterior acoustic enhancement (κ=0.543) were moderate.
Conclusions
For hepatic lesions larger than 2 cm, some ultrasonography (US) features might be suggestive of malignancy. We propose a lexicon that may be useful for surveillance US.

Citations

Citations to this article as recorded by  Crossref logo
  • Focal Hyperechoic Hepatic Lesions in Northern Region of Saudi Arabia: Prevalence, Radiologic Features, and Clinical Relevance
    Fatimah M. Alonzi, Mohammed J. Alsaadi, Khaled Said Karam, Essa M. Alanzi, Noura K. Alhathal, Maram F. Alreshidi, Abdulrahman M. Alfuraih
    Journal of Clinical Medicine.2025; 14(19): 6987.     CrossRef
  • Sonographic appearance of focal liver lesions and likelihood of hepatocellular carcinoma in adult Thais with chronic hepatitis B virus infection
    Sarana Suttivanich, Kamonwan Soonklang, Pantajaree Hiranrat, Surachate Siripongsakun
    Journal of Clinical Ultrasound.2024; 52(4): 377.     CrossRef
  • Direct comparison of biopsy techniques for hepatic malignancies
    Shang-Chin Huang, Ja-Der Liang, Shih-Jer Hsu, Tzu-Chan Hong, Hung-Chih Yang, Jia-Horng Kao
    Clinical and Molecular Hepatology.2021; 27(2): 305.     CrossRef
  • 20,164 View
  • 213 Download
  • 3 Web of Science
  • Crossref

Case Report

Hepatic neoplasm

Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient
Jin Ok Kim, Dae Won Jun, Hye Jin Tae, Kang Nyeong Lee, Hang Lak Lee, Oh Young Lee, Ho Soon Choi, Byung Chul Yoon, Joon Soo Hahm
Clin Mol Hepatol 2015;21(1):85-88.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.85

Tumor lysis syndrome is rare in hepatocellular carcinoma (HCC), but it has been reported more frequently recently in response to treatments such as transcatheter arterial chemoembolization (TACE), radiofrequency thermal ablation (RFTA), and sorafenib. Tumor lysis syndrome induced by low-dose steroid appears to be very unusual in HCC. We report a patient with hepatitis-C-related liver cirrhosis and HCC in whom tumor lysis syndrome occurred due to low-dose steroid (10 mg of prednisolone). The patient was a 90-year-old male who presented at the emergency room of our hospital with general weakness and poor oral intake. He had started to take prednisolone to treat adrenal insufficiency 2 days previously. Laboratory results revealed hyperuricemia, hyperphosphatemia, and increased creatinine. These abnormalities fulfilled the criteria in the Cairo-Bishop definition of tumor lysis syndrome. Although the patient received adequate hydration, severe metabolic acidosis and acute kidney injury progressed unabated. He finally developed multiple organ failure, and died 3 days after admission. This was a case of tumor lysis syndrome caused by administration of low-dose steroid in a patient with HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • High risk and low incidence diseases: Tumor lysis syndrome
    Kevin Molyneux, Jennifer Beck-Esmay, Alex Koyfman, Brit Long
    The American Journal of Emergency Medicine.2025; 98: 283.     CrossRef
  • Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report
    Miao Li, Ying-Ting Zhou, Bi-Wei Yang
    Journal of Medical Case Reports.2024;[Epub]     CrossRef
  • Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma
    Qiqi Zhang, Cheng Zu, Ruirui Jing, Youqin Feng, Yanlei Zhang, Mingming Zhang, Yuqi Lv, Jiazhen Cui, Linhui Zhou, Ye Meng, Linqin Wang, Zenan Cen, Alex H. Chang, Yongxian Hu, He Huang
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Tumor lysis syndrome in premature infant prompting early resection of a large sacrococcygeal teratoma: a case report
    Aditi Dey, Rita Wyrebek, Loraine Torres, Danilo Escoto, Fauzia Shakeel, Jennifer Mayer
    BMC Pediatrics.2023;[Epub]     CrossRef
  • Lenvatinib-Induced Tumor Lysis Syndrome in Advanced Hepatocellular Carcinoma
    Manjeet Kumar Goyal, Arshdeep Singh, Yogesh Kumar Gupta, Kanwarpal Kaur Dhaliwal, Ajit Sood
    ACG Case Reports Journal.2023; 10(9): e01139.     CrossRef
  • Tumor Lysis Syndrome in Breast Cancer
    Shivangi Maiti Sengupta, Hamed Daw
    American Journal of Therapeutics.2022; 29(1): e134.     CrossRef
  • Severe hyperkalaemia in the setting of tumour lysis syndrome
    Timothy G Scully, Geoffrey R Wong, Andrew W Teh, Han S Lim
    BMJ Case Reports.2021; 14(10): e246184.     CrossRef
  • Tumor Lysis Syndrome Following Thoracotomy Under Cardiopulmonary Bypass in a Case of Hepatocellular Carcinoma With Right Atrial and Inferior Vena Cava Tumor Thrombus
    Juey-Ming Shih
    Cureus.2021;[Epub]     CrossRef
  • Update on the prevention and treatment of tumor lysis syndrome
    Krishna Sury
    Journal of Onco-Nephrology.2019; 3(1): 19.     CrossRef
  • Tumor Lysis Syndrome in the Course of Burkitt Lymphoma Revealed by Medullar Compression
    L. Boukassa, S. B. Kinata Bambino, O. B. Ngackosso, K. Mavoungou Biatsi, H. B. Ekouele-Mbaki, P. Mawanza
    Open Journal of Modern Neurosurgery.2019; 09(04): 429.     CrossRef
  • Steroid-induced tumour lysis syndrome in small-cell lung cancer
    Fasihul Khan, Shazeen Ayub, Qurrat Mehmood, Syed Fayyaz Hussain
    Oxford Medical Case Reports.2017;[Epub]     CrossRef
  • Prednisolone

    Reactions Weekly.2016; 1584(1): 161.     CrossRef
  • Tumor Lysis-like Syndrome in Eosinophilic Disease of the Lung: A Case Report and Review of the Literature
    Seiya Urae, Kayori Tsuruoka, Sayaka Kuroya, Yugo Shibagaki
    Internal Medicine.2016; 55(20): 3029.     CrossRef
  • Tumor lysis syndrome and metastatic melanoma
    Marshall W. Meeks, Muhammad B. Hammami, Katherine J. Robbins, Kevin L. Cheng, Jack M. Lionberger
    Medical Oncology.2016;[Epub]     CrossRef
  • 12,106 View
  • 115 Download
  • 14 Web of Science
  • Crossref

Original Articles

Liver fibrosis, cirrhosis, and portal hypertension

Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal
Yun Jung Choi, Jeong Han Kim, Ja Kyung Koo, Cho I Lee, Ji Young Lee, Jae Hoon Yang, Soon Young Ko, Won Hyeok Choe, So Young Kwon, Chang Hong Lee
Clin Mol Hepatol 2014;20(2):185-191.
Published online June 30, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.2.185
Background/Aims

A revised classification system for renal dysfunction in patients with cirrhosis was proposed by the Acute Dialysis Quality Initiative and the International Ascites Club Working Group in 2011. The aim of this study was to determine the prevalence of renal dysfunction according to the criteria in this proposal.

Methods

The medical records of cirrhotic patients who were admitted to Konkuk University Hospital between 2006 and 2010 were reviewed retrospectively. The data obtained at first admission were collected. Acute kidney injury (AKI) and chronic kidney disease (CKD) were defined using the proposed diagnostic criteria of kidney dysfunction in cirrhosis.

Results

Six hundred and forty-three patients were admitted, of whom 190 (29.5%), 273 (42.5%), and 180 (28.0%) were Child-Pugh class A, B, and C, respectively. Eighty-three patients (12.9%) were diagnosed with AKI, the most common cause for which was dehydration (30 patients). Three patients had hepatorenal syndrome type 1 and 26 patients had prerenal-type AKI caused by volume deficiency after variceal bleeding. In addition, 22 patients (3.4%) were diagnosed with CKD, 1 patient with hepatorenal syndrome type 2, and 3 patients (0.5%) with AKI on CKD.

Conclusions

Both AKI and CKD are common among hospitalized cirrhotic patients, and often occur simultaneously (16.8%). The most common type of renal dysfunction was AKI (12.9%). Diagnosis of type 2 hepatorenal syndrome remains difficult. A prospective cohort study is warranted to evaluate the clinical course in cirrhotic patients with renal dysfunction.

Citations

Citations to this article as recorded by  Crossref logo
  • Korean Society of Nephrology 2025 evidence-based clinical practice guideline for continuous kidney replacement therapy
    Jeonghwan Lee, Donghyuk Kang, Jin Hyuk Paek, Jangwook Lee, Jung Nam An, Junseok Jeon, Kyungho Lee, Hye Ryoun Jang, Jong Hyun Jhee, Hyo Jin Kim, Harin Rhee, Sung Yoon Lim, Jihyun Yang, Seong Geun Kim, Seung Seok Han, Shin Young Ahn, Sunghoon Park, Hyun Kyu
    Kidney Research and Clinical Practice.2026; 45(Suppl 1): S1.     CrossRef
  • Korean Society of Nephrology 2025 Evidence-Based Clinical Practice Guideline for Continuous Kidney Replacement Therapy
    Jeonghwan Lee, Donghyuk Kang, Jin Hyuk Paek, Jangwook Lee, Jung Nam An, Junseok Jeon, Kyungho Lee, Hye Ryoun Jang, Jong Hyun Jhee, Hyo Jin Kim, Harin Rhee, Sung Yoon Lim, Jihyun Yang, Seong Geun Kim, Seung Seok Han, Shin Young Ahn, Sunghoon Park, Hyun Kyu
    Electrolytes & Blood Pressure.2026; 24(1): 6.     CrossRef
  • Mortality of Acute Kidney Injury in Cirrhosis: A Systematic Review and Meta‐Analysis of Over 5 Million Patients Across Different Clinical Settings
    Vasileios Lekakis, Florence Wong, Aikaterini Gkoufa, George V. Papatheodoridis, Evangelos Cholongitas
    Alimentary Pharmacology & Therapeutics.2025; 61(3): 420.     CrossRef
  • A novel risk-predicted nomogram for acute kidney injury progression in decompensated cirrhosis: a double-center study in Vietnam
    Nghia N. Nguyen, Bao T. Nguyen, Thuy D. T. Nguyen, Tam T. T. Tran, Tan N. H. Mai, Huyen N. T. Le, Hoang N. Dang, Vy B. N. Nguyen, Nhi Y. T. Ngo, Cuong T. Vo
    International Urology and Nephrology.2025; 57(7): 2279.     CrossRef
  • Gynura procumbens leaf extract-loaded self-microemulsifying drug delivery system offers enhanced protective effects in the hepatorenal organs of the experimental rats
    Manik Chandra Shill, Md. Faisal Bin Jalal, Madhabi Lata Shuma, Patricia Prova Mollick, Md. Abdul Muhit, Shimul Halder, Miquel Vall-llosera Camps
    PLOS ONE.2025; 20(2): e0304435.     CrossRef
  • Biopharmaceutical characterization of Ajwain (Carum copticum) seed extract-loaded self-microemulsifying drug delivery system for enhanced hepatoprotective and nephroprotective activity
    Shimul Halder, Fatema-Tuz-Zohora, Tania Ahmed Chowdhury, Leon Bhowmik, Madhabi Lata Shuma, Harinarayan Das, Sulobh Sarkar, Md. Abdul Muhit, Manik Chandra Shill
    Scientific Reports.2025;[Epub]     CrossRef
  • Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes
    Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    The Journal of Infectious Diseases.2024; 229(1): 108.     CrossRef
  • Study of prevalence, risk factors for acute kidney injury, and mortality in liver cirrhosis patients
    Pooja Basthi Mohan, Shankar Prasad Nagaraju, Balaji Musunuri, Siddheesh Rajpurohit, Ganesh Bhat, Shiran Shetty
    Irish Journal of Medical Science (1971 -).2024; 193(4): 1817.     CrossRef
  • Incidence and risk factors of acute kidney injury in cirrhosis: a systematic review and meta-analysis of 5,202,232 outpatients, inpatients, and ICU-admitted patients
    Vasileios Lekakis, Aikaterini Gkoufa, John Vlachogiannakos, George V. Papatheodoridis, Evangelos Cholongitas
    Expert Review of Gastroenterology & Hepatology.2024; 18(7): 377.     CrossRef
  • Acute kidney injury development and impact on clinical and economic outcomes in patients with cirrhosis: an observational cohort study over a 10-year period
    Osama Y. Alshogran, Shoroq M. Altawalbeh, Eman M. Almestarihi
    European Journal of Gastroenterology & Hepatology.2023; 35(4): 497.     CrossRef
  • Addition of Kidney Dysfunction Type to MELD-Na for the Prediction of Survival in Cirrhotic Patients Awaiting Liver Transplantation in Comparison with MELD 3.0 with Albumin
    Kyeong-Min Yeom, Jong-In Chang, Jeong-Ju Yoo, Ji Eun Moon, Dong Hyun Sinn, Young Seok Kim, Sang Gyune Kim
    Diagnostics.2023; 14(1): 39.     CrossRef
  • Acute Kidney Injury in Patients with Liver Cirrhosis: Prevalence, Predictors, and In‐Hospital Mortality at a District Hospital in Ghana
    Amoako Duah, Francisca Duah, Daniel Ampofo-Boobi, Bright Peprah Addo, Foster Osei-Poku, Adwoa Agyei-Nkansah, Maria Irene Bellini
    BioMed Research International.2022;[Epub]     CrossRef
  • Impact of acute kidney injury on the risk of mortality in patients with cirrhosis: a systematic review and meta-analysis
    Yunfeng Ning, Xiaoyue Zou, Jing Xu, Xiao Wang, Min Ding, Hulin Lu
    Renal Failure.2022; 44(1): 1934.     CrossRef
  • Keeping Patients with End-Stage Liver Disease Alive While Awaiting Transplant
    Andres F. Carrion, Paul Martin
    Clinics in Liver Disease.2021; 25(1): 103.     CrossRef
  • Chronic renal dysfunction in cirrhosis: A new frontier in hepatology
    Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand
    World Journal of Gastroenterology.2021; 27(11): 990.     CrossRef
  • Predictors of Development of Hepatorenal Syndrome in Hospitalized Cirrhotic Patients with Acute Kidney Injury
    Roula Sasso, Ahmad Abou Yassine, Liliane Deeb
    Journal of Clinical Medicine.2021; 10(23): 5621.     CrossRef
  • Urinary neutrophil gelatinase-associated lipocalin: Acute kidney injury in liver cirrhosis
    Pooja Basthi Mohan, Shankar Prasad Nagaraju, Dharshan Rangaswamy, Balaji Musunuri, Ravindra Prabhu Attur, Ganesh Bhat, Shailesh, Shiran Shetty
    Clinica Chimica Acta.2021; 523: 339.     CrossRef
  • Acute kidney injury and hepatorenal syndrome in cirrhosis
    Kapil Gupta, Abhishek Bhurwal, Cindy Law, Scott Ventre, Carlos D Minacapelli, Savan Kabaria, You Li, Christopher Tait, Carolyn Catalano, Vinod K Rustgi
    World Journal of Gastroenterology.2021; 27(26): 3984.     CrossRef
  • Diagnosis and management of renal dysfunction in patients with cirrhosis
    Andres F. Carrion, Ramya Radhakrishnan, Paul Martin
    Expert Review of Gastroenterology & Hepatology.2020; 14(1): 1.     CrossRef
  • Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI?
    Zehao Tan, Wey Chyi Teoh, Kang Min Wong, Gervais Khin-Lin Wansaicheong, Kumaresan Sandrasegaran
    Clinical Imaging.2020; 62: 63.     CrossRef
  • Evaluation of Renal Disease in Patients With Cirrhosis
    Erik L. Lum, Piyavadee Homkrailas, Suphamai Bunnapradist
    Journal of Clinical Gastroenterology.2020; 54(4): 314.     CrossRef
  • Incidence, Mortality and Predictors of Acute Kidney Injury in Patients with Cirrhosis: A Systematic Review and Meta-analysis
    Raseen Tariq, Yousaf Hadi, Khusdeep Chahal, Sivani Reddy, Habeeb Salameh, Ashwani K. Singal
    Journal of Clinical and Translational Hepatology.2020; 8(2): 135.     CrossRef
  • Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma
    Paulo Henrique Lima, Boyan Fan, Joshua Bérubé, Milena Cerny, Damien Olivié, Jeanne-Marie Giard, Catherine Beauchemin, An Tang
    American Journal of Roentgenology.2019; 213(1): 17.     CrossRef
  • Impact of Chronic Kidney Disease on Outcomes in Cirrhosis
    Florence Wong, K. Rajender Reddy, Jacqueline G. O’Leary, Puneeta Tandon, Scott W. Biggins, Guadalupe Garcia‐Tsao, Benedict J. Maliakkal, Jennifer C. Lai, Michael B. Fallon, Hugo E. Vargas, Ram Subramanian, Paul J. Thuluvath, Patrick S. Kamath, Leroy Thack
    Liver Transplantation.2019; 25(6): 870.     CrossRef
  • Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score
    Hamza Waqar Bhatti, Umama Tahir, Noman Ahmed Chaudhary, Sania Bhatti, Muhammad Hafeez, Zuhair Ali Rizvi
    BMJ Open Gastroenterology.2019; 6(1): e000286.     CrossRef
  • Spectrum of hepatitis B and renal involvement
    Apurva S. Shah, Deepak N. Amarapurkar
    Liver International.2018; 38(1): 23.     CrossRef
  • Renal dysfunction in liver cirrhosis and its correlation with Child-Pugh score and MELD score
    G A Siregar, M Gurning
    IOP Conference Series: Earth and Environmental Science.2018; 125: 012214.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • The prevalence and association of chronic kidney disease and diabetes in liver cirrhosis using different estimated glomerular filtration rate equation
    Cheng-Yi Chen, Cheng-Jui Lin, Chih-Sheng Lin, Fang-Ju Sun, Chi-Feng Pan, Han-Hsiang Chen, Chih-Jen Wu
    Oncotarget.2018; 9(2): 2236.     CrossRef
  • Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?
    Andrew Davenport, Mohammed Faisal Sheikh, Edmund Lamb, Banwari Agarwal, Rajiv Jalan
    Kidney International.2017; 92(5): 1058.     CrossRef
  • Clinical Outcomes of Peritoneal Dialysis in End-Stage Renal Disease Patients with Liver Cirrhosis: A Propensity Score Matching Study
    Su Mi Lee, Young Ki Son, Seong Eun Kim, Won Suk An
    Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis.2017; 37(3): 314.     CrossRef
  • Appréciation du débit de filtration glomérulaire et de la dysfonction rénale chez le cirrhotique
    C. Mousseaux, A. Bouguerba, S. Ayed, J. Barchasz, M. Boukari, D. Goldgran-Toledano, C. Bornstain, F. Vincent
    Réanimation.2016; 25(S3): 137.     CrossRef
  • Assessment of renal functions in patients of chronic liver disease
    H. K. Aggarwal, Deepak Jain, Suhas Singla, Promil Jain
    Renal Failure.2015; 37(9): 1457.     CrossRef
  • 13,937 View
  • 122 Download
  • 38 Web of Science
  • Crossref

Viral hepatitis

Changes in the seroprevalence of IgG anti-hepatitis A virus between 2001 and 2013: experience at a single center in Korea
Sung Jun Chung, Tae Yeob Kim, Sun Min Kim, Min Roh, Mi Yeon Yu, Jung Hoon Lee, ChangKyo Oh, Eun Young Lee, Seung Lee, Yong Cheol Jeon, Kyo-Sang Yoo, Joo Hyun Sohn
Clin Mol Hepatol 2014;20(2):162-167.
Published online June 30, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.2.162
Background/Aims

The incidence of symptomatic hepatitis A reportedly increased among 20- to 40-year-old Korean during the late 2000s. Vaccination against hepatitis A was commenced in the late 1990s and was extended to children aged <10 years. In the present study we analyzed the changes in the seroprevalence of IgG anti-hepatitis A virus (HAV) over the past 13 years.

Methods

Overall, 4903 subjects who visited our hospital between January 2001 and December 2013 were studied. The seroprevalence of IgG anti-HAV was analyzed according to age and sex. In addition, the seroprevalence of IgG anti-HAV was compared among 12 age groups and among the following time periods: early 2000s (2001-2003), mid-to-late 2000s (2006-2008), and early 2010s (2011-2013). The chi-square test for trend was used for statistical analysis.

Results

The seroprevalence of IgG anti-HAV did not differ significantly between the sexes. Furthermore, compared to the seroprevalence of IgG anti-HAV in the early 2000s and mid-to-late 2000s, that in the early 2010s was markedly increased among individuals aged 1-14 years and decreased among those aged 25-44 years (P<0.01). We also found that the seroprevalence of IgG anti-HAV in individuals aged 25-44 years in the early 2010s was lower than that in the early 2000s and mid-to-late 2000s.

Conclusions

The number of symptomatic HAV infection cases in Korea is decreasing, but the seroprevalence of IgG anti-HAV is low in the active population.

Citations

Citations to this article as recorded by  Crossref logo
  • The chronological changes in the seroprevalence of anti-hepatitis A virus IgG from 2005 to 2019: Experience at four centers in the capital area of South Korea
    Dae Hyun Lim, Won Sohn, Jae Yoon Jeong, Hyunwoo Oh, Jae Gon Lee, Eileen L. Yoon, Tae Yeob Kim, Seungwoo Nam, Joo Hyun Sohn
    Medicine.2022; 101(48): e31639.     CrossRef
  • Seropositive rate of the anti-hepatitis A immunoglobulin G antibody in maintenance hemodialysis subjects from two hospitals in Korea
    Hyunsuk Kim, Jiwon Ryu, Young-Ki Lee, Myung Jin Choi, Ajin Cho, Ja-Ryong Koo, Sae Yun Baik, Eun Hee Lee, Jong-Woo Yoon, Jung-Woo Noh
    The Korean Journal of Internal Medicine.2019; 34(6): 1297.     CrossRef
  • Seroprevalence of Hepatitis A Virus among Healthy Individuals in Birjand, Eastern Region of Iran
    Neda Mahavar, Mohammad Fereidouni, Masood Ziaee
    Hepatitis Monthly.2018;[Epub]     CrossRef
  • Seroepidemiology of Hepatitis Viruses and Hepatitis B Genotypes of Female Marriage Immigrants in Korea
    Jae-Cheol Kwon, Hye Young Chang, Oh Young Kwon, Ji Hoon Park, In Soo Oh, Hyung Joon Kim, Jun Hyung Lee, Ha-Jung Roh, Hyun Woong Lee
    Yonsei Medical Journal.2018; 59(9): 1072.     CrossRef
  • Nationwide Seropositivity of Hepatitis A in Republic of Korea from 2005 to 2014, before and after the Outbreak Peak in 2009
    Kyung-Ah Kim, Anna Lee, Moran Ki, Sook-Hyang Jeong, Yury E. Khudyakov
    PLOS ONE.2017; 12(1): e0170432.     CrossRef
  • Hepatitis A Outbreak Among Men Who Have Sex With Men in a Country of Low Endemicity of Hepatitis A Infection
    Guan-Jhou Chen, Kuan-Yin Lin, Chien-Ching Hung, Shan-Chwen Chang
    The Journal of Infectious Diseases.2017; 215(8): 1339.     CrossRef
  • CXCL10 is produced in hepatitis A virus-infected cells in an IRF3-dependent but IFN-independent manner
    Pil Soo Sung, Seon-Hui Hong, Jeewon Lee, Su-Hyung Park, Seung Kew Yoon, Woo Jin Chung, Eui-Cheol Shin
    Scientific Reports.2017;[Epub]     CrossRef
  • Current status and strategies for the control of viral hepatitis A in Korea
    Eileen L. Yoon, Dong Hyun Sinn, Hyun Woong Lee, Ji Hoon Kim
    Clinical and Molecular Hepatology.2017; 23(3): 196.     CrossRef
  • Seroprevalence and disease burden of acute hepatitis A in adult population in South Korea
    Jin Gu Yoon, Min Joo Choi, Jae Won Yoon, Ji Yun Noh, Joon Young Song, Hee Jin Cheong, Woo Joo Kim, Sheng-Nan Lu
    PLOS ONE.2017; 12(10): e0186257.     CrossRef
  • Hepatitis A in Korea from 2011 to 2013: Current Epidemiologic Status and Regional Distribution
    Shinje Moon, Jun Hee Han, Geun-Ryang Bae, Enhi Cho, Bongyoung Kim
    Journal of Korean Medical Science.2016; 31(1): 67.     CrossRef
  • Comparative Analysis of Liver Injury-Associated Cytokines in Acute Hepatitis A and B
    So Youn Shin, Sook-Hyang Jeong, Pil Soo Sung, Jino Lee, Hyung Joon Kim, Hyun Woong Lee, Eui-Cheol Shin
    Yonsei Medical Journal.2016; 57(3): 652.     CrossRef
  • Travel Pattern and Prescription Analysis at a Single Travel Clinic Specialized for Yellow Fever Vaccination in South Korea
    Bum Sik Chin, Jae Yoon Kim, Sara Gianella, Myunghee Lee
    Infection & Chemotherapy.2016; 48(1): 20.     CrossRef
  • Age-period-cohort analysis of hepatitis A incidence rates in Korea from 2002 to 2012
    Joo Yeon Seo, Sungyong Choi, BoYoul Choi, Moran Ki
    Epidemiology and Health.2016; 38: e2016040.     CrossRef
  • Seroprevalence of Hepatitis A and B Virus Antibody of Employees among Three Companies with Different Health Policy
    Hyun Min Koh, Jun Seok Son
    Journal of Korean Society of Occupational and Environmental Hygiene.2015; 25(2): 229.     CrossRef
  • 12,171 View
  • 91 Download
  • 13 Web of Science
  • Crossref

Steatotic liver disease

Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH
Min Yong Yoon, Jun Mo Sung, Chang Seok Song, Won Young Lee, Eun Jung Rhee, Jun Ho Shin, Chang Hak Yoo, Seoung Wan Chae, Ja Yeon Kim, Wook Jin, Yong Kyun Cho
Korean J Hepatol 2012;18(3):279-286.
Published online September 25, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.3.279
Background/Aims

Adipose tissue is an active endocrine organ that secretes various metabolically important substances including adipokines, which represent a link between insulin resistance and nonalcoholic steatohepatitis (NASH). The factors responsible for the progression from simple steatosis to steatohepatitis remain elusive, but adipokine imbalance may play a pivotal role. We evaluated the expressions of adipokines such as visfatin, adipocyte-fatty-acid-binding protein (A-FABP), and retinol-binding protein-4 (RBP-4) in serum and tissue. The aim was to discover whether these adipokines are potential predictors of NASH.

Methods

Polymerase chain reaction, quantification of mRNA, and Western blots encoding A-FABP, RBP-4, and visfatin were used to study tissue samples from the liver, and visceral and subcutaneous adipose tissue. The tissue samples were from biopsy specimens obtained from patients with proven NASH who were undergoing laparoscopic cholecystectomy due to gallbladder polyps.

Results

Patients were classified into two groups: NASH, n=10 and non-NASH, n=20 according to their nonalcoholic fatty liver disease Activity Score. Although serum A-FABP levels did not differ between the two groups, the expressions of A-FABP mRNA and protein in the visceral adipose tissue were significantly higher in NASH group than in non-NASH group (104.34 vs. 97.05, P<0.05, and 190.01 vs. 95.15, P<0.01, respectively). Furthermore, the A-FABP protein expression ratio between visceral adipose tissue and liver was higher in NASH group than in non-NASH group (4.38 vs. 1.64, P<0.05).

Conclusions

NASH patients had higher levels of A-FABP expression in their visceral fat compared to non-NASH patients. This differential A-FABP expression may predispose patients to the progressive form of NASH.

Citations

Citations to this article as recorded by  Crossref logo
  • The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
    Milton Packer
    JACC.2025; 86(16): 1269.     CrossRef
  • FABP4 Expression in Subcutaneous Adipose Tissue Is Independently Associated with Circulating Triglycerides in Obesity
    Óscar Osorio-Conles, Ainitze Ibarzabal, José María Balibrea, Josep Vidal, Emilio Ortega, Ana de Hollanda
    Journal of Clinical Medicine.2023; 12(3): 1013.     CrossRef
  • Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease
    Juan Moreno-Vedia, Josefa Girona, Daiana Ibarretxe, Lluís Masana, Ricardo Rodríguez-Calvo
    Biomedicines.2022; 10(1): 197.     CrossRef
  • Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
    Vera Francisco, Maria Jesus Sanz, José T. Real, Patrice Marques, Maurizio Capuozzo, Djedjiga Ait Eldjoudi, Oreste Gualillo
    Biology.2022; 11(8): 1237.     CrossRef
  • Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis
    Abdulrahman Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Dan L. Dumitrascu
    Journal of Clinical Medicine.2021; 10(14): 3029.     CrossRef
  • Serum adipocyte fatty acid‐binding protein levels are associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus
    Min Ding, Jian‐Ying Shi, Yun‐Zhi XING, Bei Sun, Qian‐Hua Fang, Jing‐Yun Zhang, Qiu‐Mei Zhang, Li‐Ming Chen, De‐min Yu, Chun‐Jun Li
    Journal of Diabetes.2018; 10(6): 478.     CrossRef
  • Adipokines in nonalcoholic fatty liver disease
    Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
    Metabolism.2016; 65(8): 1062.     CrossRef
  • Association of recently described adipokines with liver histology in biopsy‐proven non‐alcoholic fatty liver disease: a systematic review
    M. Bekaert, X. Verhelst, A. Geerts, B. Lapauw, P. Calders
    Obesity Reviews.2016; 17(1): 68.     CrossRef
  • Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography
    Chi-Sheng Hung, Yen-Wen Wu, Jei-Yie Huang, Pei-Ying Hsu, Ming-Fong Chen, Xin-Liang Ma
    PLoS ONE.2014; 9(5): e97710.     CrossRef
  • Serum visfatin in nonalcoholic fatty liver disease
    Stergios A. Polyzos, Jannis Kountouras, lordanis Romiopoulos, Vaia Polymerou
    Annals of Hepatology.2014; 13(1): 150.     CrossRef
  • Systems biology of adipose tissue metabolism: regulation of growth, signaling and inflammation
    Sara Manteiga, Kyungoh Choi, Arul Jayaraman, Kyongbum Lee
    WIREs Systems Biology and Medicine.2013; 5(4): 425.     CrossRef
  • Metabolically Protective Cytokines Adiponectin and Fibroblast Growth Factor-21 Are Increased by Acute Overfeeding in Healthy Humans
    Leonie K. Heilbronn, Lesley V. Campbell, Aimin Xu, Dorit Samocha-Bonet, Jose Galgani
    PLoS ONE.2013; 8(10): e78864.     CrossRef
  • 10,105 View
  • 79 Download
  • Crossref
Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines
Hyun Ju Lee, Jasung Rho, Shao Ran Gui, Mi Kyung Kim, Yu Kyoung Lee, Yeon Sook Lee, Jeong Eun Kim, Euna Cho, Mong Cho, Tae-Ho Hwang
Korean J Hepatol 2011;17(3):213-219.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.213
Background/Aims

JX-594 is an oncolytic virus derived from the Wyeth vaccinia strain that causes replication-dependent cytolysis and antitumor immunity. Starting with a cross-examination of clinical-trial samples from advanced hepatocellular carcinoma patients having high levels of aldosterone and virus amplification in JX-594 treatment, we investigated the association between virus amplification and aldosterone in human cancer cell lines.

Methods

Cell proliferation was determined by a cell-counting-kit-based colorimetric assay, and vaccinia virus quantitation was performed by quantitative polymerase chain reaction (qPCR) and a viral plaque assay. Also, the intracellular pH was measured using a pH-sensitive dye.

Results

Simultaneous treatment with JX-594 and aldosterone significantly increased viral replication in A2780, PC-3, and HepG2 cell lines, but not in U2OS cell lines. Furthermore, the aldosterone treatment time altered the JX-594 replication according to the cell line. The JX-594 replication peaked after 48 and 24 hours of treatment in PC-3 and HepG2 cells, respectively. qPCR showed that JX-594 entry across the plasma membrane was increased, however, the changes are not significant by the treatment. This was inhibited by treatment with spironolactone (an aldosterone-receptor inhibitor). JX-594 entry was significantly decreased by treatment with EIPA [5-(N-ethyl-N-isopropyl)amiloride; a Na+/H+-exchange inhibitor], but aldosterone significantly restored JX-594 entry even in the presence of EIPA. Intracellular alkalization was observed after aldosterone treatment but was acidified by EIPA treatment.

Conclusions

Aldosterone stimulates JX-594 amplification via increased virus entry by affecting the H+ gradient.

Citations

Citations to this article as recorded by  Crossref logo
  • Research progress and development potential of oncolytic vaccinia virus
    Xinyu Zhang, Jiangshan He, Yiming Shao
    Chinese Medical Journal.2025; 138(7): 777.     CrossRef
  • Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
    Nabil V Sayour, Ágnes M Paál, Pietro Ameri, Wouter C Meijers, Giorgio Minotti, Ioanna Andreadou, Antonella Lombardo, Massimiliano Camilli, Heinz Drexel, Erik Lerkevang Grove, Gheorghe Andrei Dan, Andreea Ivanescu, Anne Grete Semb, Gianluigi Savarese, Dobr
    European Heart Journal.2024; 45(14): 1224.     CrossRef
  • Recent progress in combination therapy of oncolytic vaccinia virus
    Seyedeh Nasim Mirbahari, Miles Da Silva, Abril Ixchel Muñoz Zúñiga, Nika Kooshki Zamani, Gabriel St-Laurent, Mehdi Totonchi, Taha Azad
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • 9,645 View
  • 45 Download
  • Crossref
The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care
Hyuk Soo Eun, Min Jung Kim, Hye Jin Kim, Kwang Hun Ko, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Heon Young Lee, Byung Seok Lee
Korean J Hepatol 2011;17(3):189-198.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.189
Background/Aims

This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC).

Methods

From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in survival between the two groups was done to investigate the efficacy of RT.

Results

Under the analysis in survival, the mean survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha fetoprotein was an independent predictors of worse overall survival rate in patients.

Conclusions

We found that the survival of patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good option for in patients with advanced HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Characteristics and survival of advanced untreated hepatocellular carcinoma of non-viral etiology
    Senarath Pathiranage Nimasha Ekanayaka, Nathasha Luke, Suchintha Bandara Thilakarathne, Anuradha Dassanayake, Mahiman Bhaagya Gunetilleke, Madunil A. Niriella, Rohan Chaminda Siriwardana
    Indian Journal of Gastroenterology.2024; 43(6): 1176.     CrossRef
  • Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma
    Kuan-Wei Huang, Yu-Tsung Lai, Guann-Jen Chern, Shao-Feng Huang, Chia-Lung Tsai, Yun-Chieh Sung, Cheng-Chin Chiang, Pi-Bei Hwang, Ting-Lun Ho, Rui-Lin Huang, Ting-Yun Shiue, Yunching Chen, Sheng-Kai Wang
    Biomacromolecules.2018; 19(6): 2330.     CrossRef
  • Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
    Jeong Il Yu, Hee Chul Park
    World Journal of Gastroenterology.2016; 22(30): 6851.     CrossRef
  • 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2015; 16(3): 465.     CrossRef
  • Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives
    Jan Erik Slotta
    World Journal of Hepatology.2015; 7(9): 1168.     CrossRef
  • Considerations for Radiation Therapy in Hepatocellular Carcinoma: The Radiation Oncologists' Perspective
    Jeong Il Yu, Hee Chul Park
    Digestive Diseases.2014; 32(6): 755.     CrossRef
  • 10,068 View
  • 73 Download
  • Crossref
Case Report
A case of concomitant Gilbert's syndrome and hereditary spherocytosis
Hee Jung Lee, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Jae Kyu Sung, Byung Seok Lee, Hyun Yong Jeong, Heon Young Lee, Young Jae Eu
Korean J Hepatol 2010;16(3):321-324.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.321

We describe moderate hyperbilirubinemia in a 28-year-old man who suffered from gallstones and splenomegaly, with combined disorders of hereditary spherocytosis (HS) and Gilbert's syndrome (GS). Since it is difficult to diagnose HS in the absence of signs of anemia, we evaluated both the genetic mutation in the UGT1A1 gene and abnormalities in the erythrocyte membrane protein; the former was heterozygous for a UGT1A1 allele with three mutations and the latter was partially deficient in ankyrin expression. This is the first report of the concomitance of HS and GS with three heterozygous mutations [T-3279G, A (TA)7TAA, and G211A] in the UGT1A1 gene.

Citations

Citations to this article as recorded by  Crossref logo
  • Gilbert syndrome in patients with inherited hemolytic anemia modifies the clinical phenotype
    Anika Agrawal, Jagdish Chandra
    Pediatric Hematology Oncology Journal.2024; 9(2): 62.     CrossRef
  • A Case of Adult Hereditary Spherocytosis Concomitant with Gilbert Syndrome Caused by Mutations in SPTB and UGT1A1
    Yang Gou, Ping Wang, Wucheng Yang, Yimei Feng, Xiangui Peng, Hong Liu, Shuiqing Liu, Xi Zhang
    Journal of Inflammation Research.2024; Volume 17: 5977.     CrossRef
  • Primary myelofibrosis with thrombophilia as first symptom combined with thalassemia and Gilbert syndrome: A case report
    Guzailinuer Wufuer, Kaisaer Wufuer, Tu Ba, Tao Cui, Ling Tao, Ling Fu, Ming Mao, Ming-Hui Duan
    World Journal of Clinical Cases.2022; 10(13): 4161.     CrossRef
  • Gilbert's Syndrome, Bilirubin Level and UGT1A1∗28 Genotype in Men of North-West Region of Russia
    Andrei Ivanov, Elena Semenova
    Journal of Clinical and Experimental Hepatology.2021; 11(6): 691.     CrossRef
  • Gilbert’s syndrome coexisting with hereditary spherocytosis might not be rare: Six case reports
    Ling-Ling Kang, Ze-Lin Liu, Hou-De Zhang
    World Journal of Clinical Cases.2020; 8(10): 2001.     CrossRef
  • Molecular Genetic Mechanisms of Hereditary Spherocytosis: Current Perspectives
    Ben-Jin He, Lin Liao, Zeng-Fu Deng, Yi-Feng Tao, Yu-Chan Xu, Fa-Quan Lin
    Acta Haematologica.2018; 139(1): 60.     CrossRef
  • Gilbert Syndrome with Concomitant Hereditary Spherocytosis Presenting with Moderate Unconjugated Hyperbilirubinemia
    Mitsuhiko Aiso, Minami Yagi, Atsushi Tanaka, Kotaro Miura, Ryo Miura, Toshihiko Arizumi, Yoriyuki Takamori, Sayuri Nakahara, Yoshihiro Maruo, Hajime Takikawa
    Internal Medicine.2017; 56(6): 661.     CrossRef
  • Scoliosis in a Patient With Gilbert Syndrome
    Zheng Li, Jianxiong Shen, Jinqian Liang
    Medicine.2015; 94(47): e2147.     CrossRef
  • Coexistence of Gilbert Syndrome and Hereditary Spherocytosis in a Child Presenting with Extreme Jaundice
    Jae Hee Lee, Kyung Rye Moon
    Pediatric Gastroenterology, Hepatology & Nutrition.2014; 17(4): 266.     CrossRef
  • A Case of Hereditary Spherocytosis Coexisting with Gilbert's Syndrome
    Min-Jae Lee, Yoon Hwan Chang, Seung-Hwa Kang, Se-Kwon Mun, Heyjin Kim, Chul Ju Han, Jin Kim, Hye Jin Kang
    The Korean Journal of Gastroenterology.2013; 61(3): 166.     CrossRef
  • Severe unconjugated hyperbilirubinaemia: one and one makes three?
    Kushal Naha, Sowjanya Dasari, G Vivek, Manjunath Hande, Vasudev Acharya
    BMJ Case Reports.2013; 2013: bcr2013009962.     CrossRef
  • 10,641 View
  • 73 Download
  • Crossref